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Summary
This thesis is a compilation of 5 different projects. A brief summary for each project 
is presented below.
A Comparison o f  a Bubble-Wrap Bag and a Mountain Rescue Casualty Bag
In a Cold Windy Environment
Reports from Norwegian mountain rescue teams suggest that one layer of bubble- 
wrap (BW) around a casualty requiring evacuation is useful in preventing loss of body 
heat. The aim of this study was to compare a BW bag against a previously evaluated 
easualty bag (CB) currently in use by some Scottish mountain rescue teams. Twelve 
male subjects [21+1.3 years, body mass 71.9+4.2 kg, % body fat 12.7+2.3% and 
height 177+ 6 cm] each participated in 2 tests (one for each bag). Tests were earried 
out in a cold (-10^0), windy (wind speed 2.7 m.sec'^) environment. The bags were 
eompared using physiological and subjective responses of the participating subjects. 
The tests were scheduled to last 60 minutes. Core and skin site temperatures (chest, 
arm, thigh and ealf) were recorded. Oxygen consumption (V0 2 ), heart rate, subjective 
cold perception ratings and perception of shivering were also recorded at regular 
intervals throughout the tests. Confidence Intervals (95% CTs) showed that the mean 
skin temperature for the bubble-wrap was between 3.9 and 5.2°C lower than the 
casualty bag at 60 mln. For Cold Comfort at 60 min, the bubble-wrap was between
0.7 and 3.3 units (95% CFs) higher (colder) than the casualty bag. There were no 
significant differences for drop in core temperature, V0 2  and heart rate. It was 
concluded that BW offers less protection against the imposed environment than the 
CB.
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Factors Affecting a Climber’s Ability to Ascend 
Mont Blanc
The aim of the study was to determine the factors affecting a climber’s ability to 
ascend Mont Blanc (4807m) using a number of variables collected at the Gouter Hut 
(3817m) before and after an attempted aseent on the Mont Blanc summit. 285 
subjects [49 females [35+11 years]; and 236 males [28+12 years]) were tested at 
3817m prior to their ascent of Mont Blanc. Demographic information and height 
ascended in the past 14 days were recorded. End tidal CO2 (PETCO2), arterial oxygen 
saturation (Sa02), heart rate (HR) and respiratory rate (RR) were measured using a 
Capnograph (Nellcor Patrick NPB75). Acute mountain sickness (AMS) scores were 
assessed using the Lake Louise scoring scale. Of the 285 subjects tested, summit 
information is available for 216 subjects. Of these, 198 are known to have reached 
summit, 12 are known to have failed, and 6 turned back in order to accompany a 
troubled friend. None of the subjects who attained 4000m in the previous 14 days 
failed to reach the summit. Previous recent exposure to an altitude of 4000m resulted 
in faster ascent times, higher Sa02 and lower raw AMS scores than those who had not 
been above 3000m in the previous 14 days. Older climbers (>57 years) and females 
had slower ascent times than young males. Climbing Profile over the previous 14 days 
significantly affected the ascent outcome and ascent times. Recent exposure to over 
4000m confers an advantage to those who wish to ascend a 4800m peak.
Performance at Altitude and 
Angiotensin Converting Enzyme Genotype
The ‘insertion’ (1) rather than ‘deletion’ (D) variant of the human Angiotensin 
Converting Enzyme (ACE) gene is associated with both lower tissue ACE activity 
and enhanced performance at high altitude. The aim of the study was to examine 
whether the onset of acute mountain sickness (AMS), and further performance on 
reaching the summit of Mont Blanc are influenced by the ACE 1/D polymorphism. 
284 climbers (86 DD, 142 ID, 56 11) had assessment of their AMS status and 
reeording their physiological measurements (PETCO2 , Sa02, HR, RR) upon anival to
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the Gouter hut (3807m) on Day 1, and again on Day 2 after an attempted ascent to the 
summit of Mont Blanc (4807m). Success in reaching the summit was genotype- 
dependent (88 % of DD, 95 % of ID, and 100% of II individuals; p=0.048); I allele 
frequeney for those reaching the summit was 0.46 compared to 0.21 for those who did 
not (p=0.01). The onset of AMS on Day 1 appeared to be dependent on genotype 
(p=0.003), but with those heterozygous being less affected. ACE genotype was not 
associated either with AMS onset or severity on Day 2. Furtheiinore, the ACE I/D 
genotype was not assoeiated with any of the tested physiological measurements on 
either Day 1 or 2. The II genotype is assoeiated with successful high altitude ascent, 
albeit an association not explicable by genotype-dependence on AMS onset or 
severity.
The Effect o f ACE Genotype and Hypoxic Ventilatory Response 
On Arterial Oxygen Saturation and other Physiological Measurements 
During a Staged Ascent to 5000m
The aims of this study were to consider the role of the ACE genotype on daily SaOz, 
HR and AMS dui'ing gradual ascent to altitude (5000m). Furthermore, the speed of 
Hypoxic Ventilatory Response, measured during rest at sea level, was used to predict 
the daily physiological responses of SaOz, HR, and AMS, while any ACE genotype 
related differences on HVR were eonsidered. 55 subjects (33 males [36+12 years]; 22 
females [32+6 years] members of a reseai’eh expedition to Nepal, volunteered for the 
study. Their HVR and ACE genotype were determined prior the expedition, and their 
physiological measurements (AMS, SaOi, HR) were recorded daily in the Nepalese 
Himalayas during a trek from Tumlingtar (330m) to Chamlang BC (5000m). It was 
found that the II genotype individuals had lower daily SaO^ (a borderline significance 
p=0.4) contrary to previous research, whereas daily HR and AMS did not differ 
between genotypes. There were no differences in HVR by genotypes, and no 
differences were found in the daily values of Sa02, HR, and AMS with respect to the 
speed of HVR. The slow aseent profile is likely to have acclimatized this group. 
Furthermore, the uneven genotype distribution (5 II, 19DD, 21 ID) may have tainted 
the results.
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ACE Genotype and Mount Everest
The angiotensin converting enzyme gene has been previously associated with elite 
mountaineering status. We sought such an advantage in a prospeetive study of those 
attempting the aseent of the highest mountain on earth, Mount Everest (8850m). 64
high altitude mountaineers (58 males [36+ 8.8 years] 6 females [33.1+ 4.6 years]) 
were recruited from both Everest base eamps (North side-Tibet and South side-Nepal) 
prior to their summit attempts in the spring of 2004. Their ACE genotype was 
determined, and their performance on the mountain recorded. Amongst successful 
summiteers (n = 42), genotype distribution was: 10 DD [24%], 22 ID [52%], 10 II 
[24%]; I allele frequency 0.50, and in those who failed (n=22) 4 DD [22 %], 10 ID 
[53%], 8 II [25%]; I allele frequency 0.59. There were no genotype differences in 
those who succeeded vs. those who failed, p=0.56. Although suggesting that ACE 
genotype may have little influenee upon mountaineering suecess, these data may be 
misinterpreted by the use of supplementary oxygen (in all those summiting). Finally, 
it may be that ACE genotype influences suceess more when acclimatisation time has 
been limited. Further investigations are required.
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CHAPTER 1
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1.1 Of Men and Mountains
Figure 1.1 Mount Everest, 8850m
'M y da^lCn^, thC^'Ci'O^thrCllAA^ln^^Cneii'aZtog^ther. I  c^xn/ttBH ycm /hcnv Ct 
pctiie^i€& me', aeid'WhatcPi'prcyipectctCi'. A n d 'th e ^ b e a ^ ity o fC ta ll 'r
George Leigh Mallory, 1921, who disappeared during the British 1924 Mount Everest summit attempt
(National Geographic).
When one considers that a mountain represents something quite different from a pile 
o f rocks to a mountaineer, only then one might ponder on the complexity o f why men 
attempt to ‘conquer’ the mountains. Symbolically, a mountain will represent different 
things to many: challenge, eourage, self-affirmation, self-discovery, accomplishment, 
life statement, or recognition to name a few. The concept o f a ‘death wish’ should 
also be mentioned if one supports such an idea.
"iTxe'thoF eitherycrtC'cm one'of your coinpciynCon^  may haA/C' the' 
pOiillHZCtyofdyOng', not only doe^’titop you^ doCrippCt, but Ct^ y cUmioit one' 
of the' thCngy thatrkeepyyou/goin '^'
Sir Edmund Hillary, first to successfully summit and descent Mount Everest along with Tenzing Norgay in 1953
(National Geographic).
To the ancient Greeks, Mount Olympus, 2917m, was the abode o f the ‘Gods’ and any 
mortals venturing there, did so at their own peril. Our appreciation for the hazards in 
mountainous regions has changed over the eenturies, and nowadays they have become 
the homes o f many people as well as a leisure escape for others. With the increasing
popularity of climbing and hiking on mountains, hills and moorlands, the risks for 
casualties from injury, exposure, and high altitude, are increasing as well.
In spite of good judgment, accidents do happen and the hazai’ds of mountainous 
activities include: slips on footpaths or rocks, falls caused by pitons pulling out, 
unexpected equipment failure, injuries from falling stones are common, as are 
disasters from occasional avalanches. A major concern in the mountains is 
hypothermia resulting from the cold, wind, and rain.
A high moimtainous environment presents not only weather exposure problems but 
also others assoeiated with hypoxia. Scientific interest in the physiological alterations 
due to high altitude boomed in the last century as climbers were exploring and 
climbing higher and higher mountains. High altitude laboratory and field studies, as 
well as high altitude research expeditions, ever since the late 1800’s to the present 
day, have been trying to explain hypoxia’s mysteries (West, 1998).
The human physiological limits were the one factor that preoccupied many, but as 
history has it, individual human physiology overcame scientific hypotheses and 
predictions. The two biggest milestones in the modern history of climbing as well as 
high altitude physiology were the first ascent of Mount Everest (8850m) by Sir 
Edmund Hillary and Tensing Norgay in 1953, and the first ascent of Mount Everest 
without the use of supplementary oxygen by Reinliold Messner and Peter Habeler in 
1978. However, similar attempts, as well as the pursuit of other mountaineering 
aceomplisliments, have resulted in the loss of many lives. Recently, the role of 
genetics has been implicated in the ability of certain individuals to perform more 
efficiently under a hypoxic environment and thus possibly, allowing for a selective 
advantage. In particular the mechanisms that regulate our response to low oxygen are 
influenced by small (and common) variations in our genes. If it can be show that one 
version of a gene is more common amongst mountaineers than in the normal 
population, it could then be suggested that this very gene may have an important role 
in adapting to low oxygen. The gene focus in this thesis is on the Angiotensin 
Converting Enzyme (ACE) gene.
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1.2 Hypothermia
One of the primary risks associated with mountain accidents is hypothermia. The 
hypothermie effects on the individual’s physical and mental state may be the primary 
reason why subsequent accidents happen. Ultimately, alteration of these two states 
can be detrimental to survival.
Hypothermia (hypo-, below & therm-, temperature) literally means low body core 
temperature and results from a fall in normal core temperature. Body core 
temperature in man is regulated around 37 Celsius (°C) by balancing the heat lost or 
gained. The body is divided into two different functional compartments: the ‘core’ 
and the ‘shell’; the distinction is much more conceptual than anatomical. The core 
includes the deep regions of the body including the brain and other vital organs, and 
constitutes about 60% of the total body mass. The shell includes peripheral tissues 
such as the skin, subcutaneous tissues, and muscles, all of which make up the 
remaining of the body mass. Skin temperature is variable throughout the body 
depending on the site at which it is measured, while the mean skin temperature is 
calculated by weighting the regional temperatures for the areas measured (Burton and 
Edholm, 1955). Skin temperature is very variable and low values do not necessarily 
indicate hypothermia. In naked man, skin temperature is very much dependant upon 
the environmental conditions and its values will vary according to the body’s 
responses.
1.2.1 Hypothermia Definitions
Core temperature in man has a diurnal variation of 1 to 2”C and therefore normal core 
temperature of an adult human has a range between 36 and 38*^ 0 (Claik & Edholm, 
1985). For clinical purposes, and as defined by the Royal College of Physicians 
Committee on Accidental Hypothermia, core temperature must drop below 35°C to 
signify hypothermia (Lloyd, 1986). The clinical stages of a hypothermic individual 
adopted by the Medical International Committee on Alpine Rescue are as follows 
(Marsigny, 2001):
1. 35-32°C: clear consciousness with shivering (no hospital treatment)
2. 32-28°C: impaired consciousness without shivering (hospital treatment)
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3. 28-24°C: unconscious, aggressive treatment and rapid transport
4. 24-15°C: appears dead, may be revived in some cases
5. <15°C: death likely due to irreversible hypothermia
1.2.2 Physiological Responses to Cold
In low ambient temperatures the body’s physiological mechanisms will attempt to 
maintain normal core temperature both by restricting heat loss and increasing the rate 
of heat production. Physiological responses to help maintain core temperature and 
protect the individual, include:
Peripheral Vasoconstriction
Vasoconstriction is a reflex mechanism prompted by information gathered from both 
central and peripheral thermoreceptors. Once these receptors sense a temperature 
drop, the hypothalamus causes an adrenal release of noradrenaline. Noradrenaline 
acts on the peripheral blood vessels (smooth muscle of arterioles) resulting in 
vasoconstriction. The effect will be a decreased blood flow peripherally, primarily to 
the cutaneous circulation and to non-exercising muscle. The alteration in blood flow 
will produce a cold shell, which in effect encapsulates the warm core resulting in a 
reduced skin/environment temperature gradient and thus minimizing heat loss (Toner, 
1988).
Increased Physical Activity and/or shiverins
Increased voluntary physical activity, such as walking, running, or swimming, will 
increase the rate of heat production which may then effectively balance the heat loss 
in the body. Shivering, on the other hand, is an involuntary physiological mechanism, 
and will initially compensate for the heat lost at low ambient temperatures. The 
skeletal muscles contract and relax asynchi'onously in shivering, and as there is no 
purposeful movement in this process, the main objective is to increase heat 
produetion. The heat produced by the body, tluough any means, will aid in the 
maintenance of a ‘normal’ core temperature; although, as blood flow increases to the 
muscles heat loss will also increase and thus high intensity aetivity cannot be
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sustained for long periods of time. Sometimes when the cold stress is great enough, 
heat balance is not achieved, and despite exercise, hypothermia is unavoidable.
1.2.3 Heat Balance
To maintain heat balance in the core, heat production must equal heat loss. If core 
temperatm'e Is to be maintained at equilibrium, the rate and amount of heat produced 
internally, must be exactly the same as the rate and amount of heat lost tlirough 
convection, conduction, evaporation, and radiation from the body surface. If balance 
is not achieved for example, when the environment is too cold, either by a failure to 
conserve heat or to increase heat production, then a drop in core temperature will be 
observed.
The rate of heat loss in the individual will determine how fast hypothermia sets in. 
Continuing to exercise/walk vigorously, if it is not too cold, will protect against the 
development of hypothermia. The individual who maintains a high rate of body heat 
production through physical activity that equals or exceeds the rate of heat loss from 
the body will maintain heat balance. However, once one fatigues and slows down the 
pace of activity or stops altogether, the rate of heat production fails dramatically, and 
hypothermia will most likely develop. In such cases, the individual’s hypothermic 
state is classified as accidental.
There are a number of characteristics associated with hypothermia, though not all may 
be present in all cases, the sequence of events is usually as follows: The affected 
person begins to slow down and lag behind. He is clumsy, stumbles, and falls 
frequently. Mental changes are common including apathy, incoherence, lack of co­
operation and sluired speech. Muscular weakness, cramps, and collapse may follow. 
Death could be the final outcome (Pugh, 1966).
Heat loss can be effectively prevented through the use of clothing. Appropriate 
clothing can increase the body’s insulation by means of a protective barrier between 
the body surface and the outside environment, thus allowing a state of homeothermia 
(Gonzales, 1988). However, when the clothing becomes wet it loses its insulative
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capabilities (Pascoe, 1994), and the subsequent heat loss increases further as water 
conducts heat twenty-five times more than air.
1.2.4 Exposure Hazards
Some of the causes that would make a hill-walker, climber, or anyone else in the 
mountainous environments susceptible to exposure hazards are the following (Pugh, 
1966):
• weather conditions— overtaken by harsh conditions e.g. cold, wind, rain, snow
• being benighted—not having the appropriate equipment for night survival
• insufficient clothing—inadequate protection for cold, wet, and windy conditions
• exhaustion-muscular weakness and inability to continue on and/or to find shelter
• inexperience-lack of training, errors in judgment during hazardous situations
• inadequate body insulation—when insulation is diminished thi'ough wet clothing is 
diminished or in the absence of appropriate clothing, inadequate thickness of 
subcutaneous fat will malce one even more susceptible to hypothermia
A classic and well documented sequence of events leading to accidental hypothermia 
is exemplified in the 1964 Four Inns Walking Competition in Derbyshire, UK, as 
described by Pugh (1964a). The event was held over 2 days and stalled at 06:00 his 
on the 14^ *' of March 1964 with 80, thiee-man teams leaving at 2-minute intervals. 
The temperatures for that day were estimated to be between 1 and 4®C with and a 
wind speed of 25 knots (12,9 m.sec'^), but much stronger in the hills. By 13:15 hi's 
the first updates were received that some hikers were in trouble. By late afternoon five 
distressed hikers had been brought to safety; one subsequently died. The bodies of a 
further two hikers were found 2 days later, after a search was conducted by some 800 
persons.
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Although there were only 3 fatalities, the common features were:
• Their clothing was inappropriate for the conditions as none had waterproof 
outer garments such as oilskins. Any minimal insulation initially provided 
from their clothing was subsequently lost.
• As the insulating properties from their clothing were lost, subcutaneous fat 
was the only remaining insulator. In their case, were lean with little 
subcutaneous fat.
• They collapsed around 2 his after the initial fatigue symptoms set in. On the 
other hand the participants who finished the event were able to maintain high 
rates of energy expenditure, and hence high rates of heat production, for the 
duration of the event.
1.2.5 Mountain Rescue
When accidents happen in the hills or mountains the first to provide specialised help 
to the victim is usually a mountain rescue team. Most mountain rescues involve 
lengthy searches, carrying heavy equipment and casualties on stretchers for prolonged 
periods, and often in severe weather conditions. Mountain rescue teams around 
Britain undertake approximately 800 critical rescues a year (Mountain Rescue 
Council, 1998). Scottish mountain rescue call-outs are frequent. In the four-yeai' 
period from 1996 to 1999, there were 1027 incidents involving 1269 people. More 
than half of these individuals had some form of an injury, and eight per cent of the 
casualties were deemed to be hypothermic (Sharp, 2001). In Scotland alone, over 30 
fatalities occur yearly arising from mountain accidents (Hearns, 2000).
A major problem is finding the victim, but once located by the rescue team and 
treated for the sustained injuries, mountain rescue missions will most likely result in 
an efficient and safe evacuation of the casualty (Waddell, 1975). He/she is placed 
inside a rescue casualty bag (injury permitting) before being laid onto a stretcher to be 
carried down. The casualty bag can reduce heat loss in the victim, offering protection 
from enviromnental conditions until taken to safety.
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1.2.6 Rewarming
The primary objective in the treatment of hypothermia is to rewarm the patient as 
safely and efficiently as possible (Dexter, 1990). The field management of a 
hypothermic victim requires re-wanning teclmiques. Depending on the situation, 
weather conditions, and the victim’s physical state, the rewarming methods can either 
be passive or/and active (Snadden, 1993):
Passive re-warming
Removal of the victim from the possibly exposed accident site, and transfer to a 
protected and safe location, will allow for core temperature to rise; this may take 
some time.
Active re-warming
The victim is re-waimed thi'ough the use of external means such as blankets, heat 
bags, airway rewarming technique, or water immersion into 40-45°C, however the 
latter may prove impractical in the field. Active re-warming should be a stepwise 
process and not an immediate and fast one. One of the dangers of rapid active re­
warming of the body’s surface will cause vasodilatation in the peripheries, and thus 
transfer of cold blood back to the core. In light of that, further cooling of the core, 
known as the ‘after-drop’, is likely to occur with the possibility for ventricular 
fibrillation resulting from chilling of the heart (Snadden, 1993).
1.2.7 Equipment For The Management of Hypothermia
The first aid management of accidental hypothermia in a remote location poses many 
problems for the rescuers. Treatment at the accident site or immediate evacuation 
often proves to be a critical decision. Iirespective however of the decision made, the 
casualty will have to be transferred to a hospital after rescue. It is important therefore 
to provide adequate external insulation to prevent further heat loss and a possible 
worsening of the casualty’s condition. Such insulation can be provided by means of a 
casualty bag. During the 1997 Accidental Mountain Hypothermia conference in 
Scotland, the use of casualty bags was emphasized (Grant et al, 1998). As they 
probably are one of the most important equipment in keeping a rescued hypothermic 
victim alive, obtaining information about the effectiveness of casualty bags is
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important. It was concluded that the need to test for casualty bag effectiveness is 
essential so that the more efficient bags can be selected for use (Grant et al, 1998).
Space Blanket
A few decades ago, the development of a revolutionary item became very popular in 
the treatment of a hypothermic victim; the ‘space blanket’. The space blanket was 
developed in the 1960’s to originally fulfill an ‘insulator’ role for industries and 
organizations. It is constructed of a sheet spattered with aluminium to make up a 
metallised plastic sheeting (MPS) otherwise known as space blanket and was 
introduced in the 70’s for survival purposes (Chadwick and Gibson, 1997). The main 
heat loss avenue from the body on land is through convection, but the space blanket 
works by reflecting radiated heat, and whereas its an excellent insulator in the vacuum 
of space, theoretically it may also reflect the very small amount of infrared radiation 
emitted by the skin provided the vacuum can be maintained on land (Royal Air Force 
Institute of Aviation, 1976). Even though the space blanket is still widely used in 
hospital settings, review reports by Chadwick and Gibson (1997) clearly highlight that 
use of the space blanket is unlikely to make a meaningful contribution to the well 
being of the patient.
Casualty Bags
Ever since the emergence of the space blanlcet, bags and blankets of different makes, 
shapes and sizes have been developed and tested. Early developments were 
metallised plastic sheeting bags (Light and Norman, 1980), heavy-gauze polythene 
bags (bivouac bag) (Grieve, 1969; Light et al, 1980), or the more recent ones 
consisting of nylon and/or neoprene outer shell with or without fleece material imier 
lining (Grant et al, 2002). Research results provide information on which bag or 
blanket would protect and insulate a victim more effectively. The latest study on 
casualty bags, currently used by mountain rescue teams, was performed by Grant et 
al, (2002) who evaluated on their insulative properties by investigating the 
physiological responses of the participating subjects.
Some researchers may question the use of human subjects in such trials and could 
propose other forms of experimentation in assessing bag efficiency; those include the 
use of a physics laboratory for the evaluation of the best equipment in terms of
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superlative insulative properties, or even the use of manikins instead of humans. 
However, information from such research would be of quantitative only value. The 
ultimate validation of any insulative equipment used by man, relies on testing with 
humans under actual conditions of intended use (Pascoe, 1994). It is only through this 
research methodology that subjective feedback and actual physiological responses can 
be gathered with great accuracy.
It seems though that not all rescue teams adopt the same equipment. In order to 
protect the victim, an effective casualty bag should have certain characteristics; it 
must be windproof, waterproof, and provide significant additional thermal insulation. 
The properties of the bag must be of high standard such that will protect a 
hypothermic victim. However, ideas for casualty bags made from different materials 
are constantly evaluated and put into effect. Therefore, the need for further testing is 
important in order to ensure the effectiveness of new equipment.
Bubble-Wrap Bag
Mountain rescue teams in Norway have adopted the use of bubble wrap as casualty 
bag material to protect their casualties. Its use may be advantageous as it is very 
cheap to make and very light to carry to rescue missions. However, no scientific 
research has thus far tested its effectiveness. Anecdotal evidence from Norwegian 
rescue teams suggests that bubble wrap has had satisfactory performances during their 
rescue missions. It is one of the aims of this thesis to test whether this is true.
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1.3 Altitude Hypoxia
At altitude there is less oxygen for the same volume of gas than at sea level, despite a 
constant percentage of oxygen in inspired air (20.93%). Altitude hypoxia results from 
a decrease in barometric pressure with increasing altitude, and can be described as the 
less than normal-sea level amount of oxygen in the inspired air (Figure 1.2).
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Figure 1.2 Relationship between altitude and inspired oxygen pressure (West, 1979).
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Partial pressure of oxygen (PO2 ) falls as oxygen is transported from ambient, to 
inspired, to alveolar, to arterial, and finally to mixed venous, forming a cascade of O2 
(Ward et al, 2000). These oxygen decrements are further exaggerated at altitude due 
to the decreased barometric pressure. Figure 1.3. The PO2 in the mixed venous blood 
is maintained at approximately the same values in both at sea level and altitude; this is 
achieved through certain processes and changes in the physiology whilst at altitude.
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Figure 1.3 PO 2 values from inspired air to mixed venous blood a sea level and in residents at an 
altitude o f  4600m (West, 2000).
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1.3.1 Physiological Changes At Altitude
Exposure of sea-level residents to altitude evokes a series of physiological responses. 
In conditions of hypoxia the lungs must take in a greater total volume of air in an 
attempt to compensate for the decreased oxygen levels (West et al, 1983; Sutton et al, 
1988). The most important physiological change during exposure to hypoxia is an 
increase in minute ventilation, otherwise called hyperventilation. The organ 
responsible for sensing the hypoxic condition is the carotid body. Situated above the 
bifurcation of the common carotid artery, the carotid body has a large blood flow and 
responds to decreased levels of oxygen in the arterial blood (PaOi), high CO], and low 
pH, while it plays an important role in the ventilatory acclimatization to hypoxia. 
Hyperventilation will aid in increasing alveolar oxygen levels (PaO]) following a 
decrease in ambient PO? when exposed to altitude. The degree of hyperventilation is 
represented by the value of alveolar carbon dioxide levels (PaCO]); as ventilation 
increases, PaCO] values will decrease (West, 1993), and can experimentally be 
measured through the value of end tidal carbon dioxide (PETCO2 ). PETCO2 drops 
immediately with altitude exposure, and gradually continues to do so, as ventilation 
increases over time whilst staying at altitude. Figure 1.4.
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Figure 1.4 Resting PETCO 2 for 2 groups measured at sea level and during 12 and 19-day sojourns at 
4300m. Values decrease due to hyperventilation (Muza et al, 2001).
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Once the decreased PO2 is sensed by the carotid bodies, the respiratory adjustments 
will take place through chemo-reflex pathways, while the reflexive increase in 
ventilation induced by hypoxia, is called the hypoxic ventilatory response (HVR). 
The increase in ventilation varies from individual to individual but does not usually 
start until about 3000m (Rahn and Otis, 1949). A brisk HVR on ascent to altitude will 
result in increased arterial oxygen saturation (Sa0 2 ) and may therefore aid in 
improving performance (Schoene et al, 1984).
Sa02 is the percentage of haemoglobin (Hb) that carries oxygen in the blood. The 
degree of arterial hypoxia can be measured by the Sa0 2  value, and whilst at altitude 
(exemplified by a fall in PO2) the saturation percentage falls. The major 
haematological adjustment at altitude is the increase in the Hb concentration in the 
blood (Pugh, 1964). Initially, Hb concentrations rise through a fall in the plasma 
volume due to dehydration caused by respiratory fluid loss, perspiration or diuresis. 
Later on though, hypoxia stimulates production of the hormone erythropoietin by the 
kidney, allowing Hb production to increase, leading to its concentration in the blood 
to rise, and resulting in an increased oxygen supply to the hypoxic tissues.
The physiological changes at altitude will aid in the individual’s acclimatization to 
altitude. Altitude acclimatization refers to the beneficial series of physiological 
changes over time by which un-acclimatized individuals respond to the reduced 
inspired PO2 . As previously mentioned, and further summarized in Figure 1.6, 
hyperventilation will help maintain Pa0 2  at high enough levels in the face of falling 
inspired PO2 , which in turn will increase Pa02 thus having a direct effect achieving a 
raised S A .  Gradual renal compensation, due to respiratory alkalosis, is another 
physiological change aiding in acclimatization. With the consequent increase in 
ventilation at altitude, arterial pressure levels of carbon dioxide will fall producing a 
respiratory alkalosis, an increase in pH. The kidneys then respond to the change in 
pH by excreting bicarbonate in urine, pH will decrease to such levels that there is less 
inliibition on the respiratory centers, and thus ventilation is increased to compensate 
towards higher pH levels again. On ascent to altitude, cardiac output (CO) will 
increase via an increase in heart rate so that more blood is moved rapidly to the tissues 
and thus increase O2 delivery, though at high altitude (HA) each unit of blood carries 
less O2 . Over time however, CO returns to normal values as a higher O2 extraction
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from the blood is achieved. Capillary density increases and enhances O2 diffusion to 
the muscles, whereas O2 supply is further aided via the increased oxygen carrying 
capacity in the blood due to the increased Hb concentration.
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Figure 1.5 Mean changes in several variables relating to ventilation in subjects at Denver (D), 1600m, 
and first 5 days at an altitude o f  4300m on Pikes Peak (Huang et al, 1984).
Nevertheless, at high altitudes of around 5000-6000m, one will not keep acclimatizing 
indefinitely to hypoxia, and as stay is prolonged, physical fitness starts to deteriorate 
(Pugh, 1962). This deterioration is characterized by mental and physical function
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decrements such as loss of appetite, fatigue, lethargy, mental slowness, poor 
judgment. As humans are truly at their physiological ‘ceiling’ at extreme altitudes, 
time spent in the ‘death zone’, 8000m and above, should be as minimal as possible as 
deterioration can be severe (West, 1993).
The factors crucial to the success or failure of acclimatization are the speed by which 
one is exposed to hypoxia (rate of ascent), the severity of hypoxia (altitude change), 
as is the ‘unique’ physiology each individual has (Houston, 1982). Inadequate 
acclimatization will most likely result in Acute Mountain Sicloiess (AMS).
1.3.2 Acute Mountain Sickness (AMS)
The first known written report available about mountain sickness has its origins in 
China, and was reported by Too Kin, a Chinese official, in 37-32 B.C. The translation 
from the Chinese reads:
c>ne'C<>m^tc>-BC0'Heud4^che^cu%d/LCttie^Heuda<:h^Mot^ ontayCn4'j aé' 
weZl'0 4 'KedyEa4^^a4^d'Sw elter HClU'. T^iey mw(Jce'Oym.04V4<^hot'th4wthi4' 
foce'turné'poZe'j hCé'heod'Ocheé'j on d'h e'h e0‘lyi4't<^voryUt. Even/the^ 
d o n Â e ^yo n d 'iw C n e 're o ^ th C ^  w a^"
(Gilbert, 1983).
AMS poses a significant risk to those individuals who venture to the high mountains. 
Of those traveling to altitudes between 2000-3000m, about 12-42% will succumb to 
the hypoxic stresses and develop Acute Mountain Sickness (Houston, 1985; 
Montgomery et al, 1989; Maggiorini et al, 1990; Honigrman et al, 1993). AMS is a 
self-limiting condition, which occurs to some degree in all un-acclimatized 
individuals who rapidly ascend to high elevations. The symptoms of AMS usually 
become evident after 6-12 hours of exposuie (Ward et al, 2000), and reach their 
maximum severity during the first and second day after exposure (Carson et al, 1969). 
High altitude headache is the most prominent symptom in AMS (Honigrman et al, 
1993) while the other common symptoms are nausea, anorexia, insomnia, fatigue, 
vomiting and dizziness (Hackett et al, 1976).
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As agreed upon at the 1993 International Hypoxia Symposium at Lake Louise, 
Canada, AMS is diagnosed when an individual has a headache and at least one more 
symptom due to a recent ascent in altitude. A diagnostic AMS scoring scale 
(Appendix A) was further proposed (Roach et al, 1993). Prior to that, classification of 
AMS during scientific research usually depended on the protocol of the study and the 
investigator’s personal assessment of the tested individual’s physiological status. The 
Lake Louise consensus AMS scoring scale has since then been validated and found 
effective in assessing the incidence of AMS (Maggiorini et al, 1998).
As previously stated the incidence and severity of AMS will depend on the ascent 
profile, particularly the rate of ascent and total height difference achieved. In skiing 
resorts in Colorado, at altitudes between 2000 and 2800m a 12% incident was 
observed (Houston, 1985). In the Southern Alps of New Zealand, around the region 
of Mount Cook (3754m), there was a 26% incidence of AMS, with the incidence 
rising to 50% for those who slept above 2500m (Murdoch and Curry, 1998). In the 
Swiss Alps at refuge huts the incidence of AMS was 9% at 2850m, 13% at 3050m, 
35% at 3650m, and 53% at 4559m (Maggiorini et al, 1990). In the Nepalese 
Himalayas (Pheriche, 4243m) it was found that 43% of the trekkers were affected 
(Hackett et al, 1976). Moreover, at the same location, the incidence was higher in 
those who started their trek at 2800m (Lukla airport) than those who trekked from 
1200m (Kathmandu), 49% versus 31% (Hackett et al, 1976). Despite the current 
knowledge on the illnesses caused by high altitude hypoxia the reasons why some 
subjects are more susceptible to LIA illnesses still remain unclear.
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1.3.3 Arterial Oxygen Saturation and Acute Mountain Sickness
AMS severity has been coiTelated to the levels of SaOz; the lower the SaCL the higher 
the degree of AMS. On anival to an altitude of 4200m, low SaOi measurements are 
associated with a higher AMS onset (Basnyat et al, 1999) and are a good predictor for 
subsequent AMS development (Roach et al, 1998), as are low levels during 
normobaric or hypobaric exposure to pikilocapnic hypoxia (Burtscher et al, 2004), or 
even nocturnal levels the night of arrival at an altitude of 4459m (Erba et al, 2004). 
However, one study has failed to show a conelation between low SaCL levels and 
AMS at an altitude of 3080m (O’Connor et al, 2004). Low arterial oxygenations at 
altitude have been attributed to hypoventilation (Hackett et al, 1982; Moore et al,
1986) and impaired gas exchange (Ki'onenberg et al, 1971; Sutton et al, 1976). 
Moreover, SaCL further decreases with exercise at high altitude (West et al, 1983) and 
such worsening hypoxemia have been attributed to both ventilation/perfusion 
inequality and diffusion limitation in the lung (Wagner et al, 1986; Wagner et al,
1987). Even though the decrease of SaCL with an increase in altitude is an immediate 
one, the onset of AMS symptoms is not as rapid.
1.3.4 Hypoxic Ventilatory Response (HVR) And Acute Mountain Siekness
It seems appropriate to infer that increased ventilation at altitude through a brisk LIVR 
and a consequent increase in SaOi levels, would protect one from AMS and enhance 
performance at altitude (Schoene et al, 1984). The documented findings however are 
divided with either a positive evidence for an HVR-AMS conelation (King and 
Robinson, 1972; Moore et al, 1986) or a lack of it (Milledge et al, 1988; Milledge et 
al, 1991; Baitsch et al, 2002). High altitude residents have a blunted HVR response 
(Severinghaus et al, 1966; Milledge and Lahiri, 1967) yet seem to be less affected by 
AMS to the same degree as lowlanders when venturing to altitude. To make matters 
more confusing, it has been shown that high altitude climbers have a more brisk HVR 
when compared to non-climbers (Schoene et al, 1982) but, it is interesting to mention 
that one of the first two climbers to reach the summit of Everest without the use of 
supplementary oxygen had a blunted HVR (Schoene et al, 1987).
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1.3.5 Acute Mountain Sickness Susceptibility And Prediction
The incidence of AMS appears to affect from about a quarter of the people who travel 
to high altitude at around 2500m to almost half at around 4000m. The physiological 
responses between individuals at altitude do not seem to be consistent (Murdoch, 
1999). Susceptibility most likely depends on the individual and there is no easy way 
to identify and predict who will succumb to the ill effects of hypoxia. Athletic fitness 
and an increased aerobic capacity do not make one ‘safe’ from AMS onset (Savourey 
et al, 1995). Anecdotal evidence reports that many elite athletes and physically fit 
individuals are more prone to AMS than are relatively unfit people when both 
ascending the same mountain. It is likely that fit mountaineers may overexert 
themselves more readily without paying attention to any warning symptoms of AMS 
and therefore are at a higher risk of developing the sickness. A similai* distribution for 
AMS incidence has been reported between males and females (Hackett et al, 1976; 
Hackett, 1980), whereas older people tend to be less susceptible than younger ones 
(Roach et al, 1995). As climbing mountains is a vigorous exercise, high intensity 
exercise has been shown to further exacerbate AMS symptoms (Roach et al, 2000).
Prediction of susceptibility on the incidence of AMS through various physiological 
measurements has been attempted through various laboratory and field studies. 
Because AMS susceptible individuals may have low ventilation at altitude, HVR has 
been investigated whether or not it can predict AMS, as previously discussed (1.3.4). 
Other investigators have proposed alternative methods for predicting AMS and have 
showed positive correlations with low end-expiratory PO2 in nomioxia (Savourey et 
al, 1995), short apnea time and a hypersensitive gag reflex (Austin and Sleigh, 1995), 
or ventilation measurements in acute normobaric hypoxia (Hoefer et al, 1999); 
however, their methods are questioned for their validity and sensitivity, and their 
findings have yet to be reproduced (Bartsch et al, 2001). Grant et al, (2002) attempted 
to predict AMS at altitude from physiological variables measured in acute normobaric 
hypoxia, but the results offered limited predicative information. Measurement of the 
arterial oxygen saturation (Sa0 2 ) upon anival at altitude has also been implemented 
as means of predicting consequent AMS (Roach et al, 1998), although the specific 
study results are only applicable for the tested altitude as Sa0 2  levels vary at different 
altitudes.
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1.3.6 Acute Mountain Sickness Treatment
AMS is a self-limiting condition and relatively well tolerated. Prophylactic treatment 
through the use of drugs is not usually taken up, as most cases will improve after 24- 
48 hours (Ward et al, 2000). However, therapy for those with a history of AMS is 
recommended. Acetazolamide (Diamox), a carbonic anhydrase inlribitor, is the 
medication of choice. It has been shown to be effective for the prevention of AMS 
thi'ough an increase in ventilation (Greene et al, 1981). The usual oral dose is 250mg 
every 8-12 houi's, starting one day before ascent and continuing for 48-72 hours at 
altitude (Greene et al, 1981). High altitude headache can be effectively treated with 
paracetamol. If symptoms arise, ascent should be stopped until they resolve, but if 
they persist a short descent of about 500m should be implemented until they disappear 
(Peacock, 1998).
1.3.7 Central Nervous System (CNS) Model Of AMS Pathophysiology
Alternative attempts to determine the development of AMS have been suggested. The 
most recent attempt to explain the pathophysiology of AMS is thi'ough a CNS model 
(Roach and Hackett, 2001). Hypoxia will cause swelling of the brain. This swelling 
has been attributed to development of cerebral oedema (Hackett et al, 1998), an 
increase in blood brain barrier (BBB) permeability (Abbott and Revest, 1991), and 
possibly an increase in cerebral blood volume (CBV) (Roach and Hackett, 2001). At 
the same time, peripherally, there is an increase in extra-cellular water levels and once 
at the brain level intracranial pressure develops by means of compression to the brain. 
Inability to buffer the pressure tlnough cerebrospinal volume capacity (Shapiro et al, 
1980) will most likely cause AMS symptoms. The cuiTent and future technological 
experimental teclmiques may make it possible in the near future to prove whether or 
not this model can be verified. The “tight fit” hypothesis of Ross (1985) that 
anatomical differences, smaller intracranial and intraspinal fluid capacities, could 
justify the unsystematic nature of AMS susceptibility in individuals is veiy attractive, 
yet not experimentally proven.
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1.3.8 High Altitude Pulmonary And Cerebral Edemas (HAPE and HACE)
Ascent to high altitude may make one prone to AMS, but the two most serious 
potential illness developments are High Altitude Pulmonary Edema (HAPE) and High 
Altitude Cerebral Edema (HACE). Although they are presented as separate entities, 
they share many clinical features but represent different degrees of severity of a 
common, yet still undiscovered, pathophysiological process (Hackett et al, 1981; 
Hackett et al, 1988).
HAPE occurs in otherwise healthy individuals who ascend to high altitude, and is a 
non-cardiogenic form of pulmonary edema resulting from a leak in the alveolar 
capillary membrane. Its development usually arises in association with rigorous 
exercise, and develops after the first day (Hackett and Roach, 1990). Past HAPE 
history will most likely result in a future episode, while high pulmonary arterial 
pressure (due to hypoxic vasoconstriction) is a marker for HAPE susceptibility in 
hypoxia (Gibbs, 1999). Further, HAPE susceptible subjects tend to have a low HVR 
(Hackett et al, 1988; Matsuzawa et al, 1989). Its clinical features, in addition to those 
of AMS, are crackles at the site of edema in the lungs, shortness of breath which is 
usually exaggerated during the night, dry cough with further development of 
production of a frothy white-yellowish or bloody sputum. Figure 1.7 shows a chest 
radiography of a patient with HAPE (left illustration) and the same patient 4 days later 
(right illustration). Typical features are asymmetrical and irregulai’ly positioned 
‘cotton woof blotches in both lungs. In treated cases, radiographic lesions clear 
rapidly (Ward et al, 2000).
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Figure 1.6 Radiograph o f patient with HAPE (left) and 4 days later (right) (W ard et al, 2000).
Furthermore, there is a decrease in exercise performance, chest tightness and pain, 
weakness, lethargy, tachycardia, and cyanosis (Sartori et al, 1997). Recommendations 
for prevention include allowing enough time for acclimatization and implementing a 
slow ascent rate. As HAPE is a life threatening condition, the best management and 
treatment is immediate descent. Unless descent is impossible to implement 
immediately, alternatives include oxygen administration (Hackett and Hombein,
1988) or the use of a portable hyperbaric bag (Shimada et al, 1996). Administration 
of vasodilators such as Nifedipine or Nitric Oxide is also an effective way of 
treatment (Oelz et al, 1989; Scherrer et al; 1996). The objective of the treatment is to 
improve arterial oxygenation, reduce pulmonary hypertension and clear the edema. 
Similarly to AMS, there is great variability to the individual susceptibility for HAPE, 
and a prediction for the condition has also yet to be found.
HACE on the other hand is considered to be the more malignant form of AMS and 
will affect un-acclimatized individuals on ascent to high altitude (Hackett, 1981). 
HACE is characterized by the same symptoms as AMS, but developing to altered 
consciousness, ataxia, coma, and even death. The most vital treatment is immediate 
descent. In addition the use of supplemental oxygen and hyperbaric bag are certainly 
recommended, as is the use of the drug Dexamethasone, all of which have been
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shown to be aid in the treatment of HACE (Johnson et al, 1984; Montgomery et al,
1989).
1.3.9 Recommendations For Safe Ascent To Altitude
Despite the seriousness of all mountain illnesses, it may be possible to prevent their 
unwanted consequences, and if caution is practiced, then an ascent can be as risk free 
as possible. To date, no tests are available that can accurately predict high altitude 
tolerance. However, precautions are advised when venturing to high mountains; 
recommendations that should be considered are the following (Ward et al, 2000; 
Bartsch et al, 2001):
• Ascent profile should be gradual, and above 3000m the ascent rate should be 
no more than 300-500m/day with a rest day every 3-4 days, however, a safe 
ascent cannot be ‘engraved in stone’ as it varies amongst individuals
• Previous altitude illness history needs to be considered; precautions should be 
taken to avoid a future illness episode
• Medical support should be available within the team and emergency 
evacuation plans should be available
• Flexibility in itinerary in order to allow for any insufficient acclimatization as 
well as treatment of any medical problems
• Preventative methods through the use of prophylactic drugs may be 
implemented
• Knowledge on how to identify AMS symptoms and when to stop the ascent, is 
also deemed important
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1.4 Genetics
Genetic predisposition undoubtedly plays a role in the development of a particular 
physical performance under a particular condition. The data presented and the 
research undertaken in this thesis focuses and examines the role of the angiotensin 
converting enzyme (ACE) gene during performance at altitude.
1.4.1 Angiotensin Converting Enzyme (ACE)
The renin-angiotensin system (RAS) is known to play a significant role in circulatory 
homeostasis. The liver produces angiotensinogen, a globulin, which is acted upon by 
the protease renin, produced by the kidney under conditions of salt or volume loss, or 
sympathetic activation, and converts it into the peptide angiotensin I (Ang I). ACE, 
circulating and membrane bound, cleaves Ang I into angiotensin II (Ang II). Ang II 
is a potent vasoconstrictor and stimulator of adrenal aldosterone release which leads 
to water and salt retention. Moreover, the RAS has a tissue-based diversity and has 
been observed in areas such as the human myocardium (Dzau, 1988), adipose tissue 
(Jonsson et al, 1994), lung (Pieruzzi et al, 1995), and skeletal muscle (Dragovic et al, 
1996).
In the human ACE gene, found on chromosome 17, a common genetic variance is 
observed. The absence (deletion, D allele) rather than the presence (insertion, I allele) 
of a 287 base pair fragment at intron 16 in the ACE gene, is associated with higher 
ACE activity. The frequency of the alleles, I and D, is roughly equally distributed, 
but variations do occur between populations of different ethnic origin. A large scale 
population study on British people, showed the ACE genotype to be divided into 24% 
of the population having the II genotype (low ACE activity), 26% having the DD 
genotype (high ACE activity), and 50% having the ID genotype (intermediate ACE 
activity) (Miller et al, 1996).
Human pathological and physiological responses have been observed and recorded 
under various stimuli in regards to a specific ACE genotype.
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1.4.2 ACE I/D Polymorphism And Human Physical Performance
The I allele has been associated with athletic endurance performance and has been 
observed in excess in rowers (Gayagay et al, 1998), distance runners (Myerson et al,
1999), marathon swimmers (Tsianos et al, 2004), and elite athletes in a variety of 
sports (Alvarez et al, 2000). Other studies however (Kaijalainen et al, 1999; Taylor et 
al, 1999; Rankinen et al, 2000b), have not been able to reproduce similar outcome, 
and this may be the result of their ‘athletic populations’ not being truly endurance 
based. In the Myerson et al, (1999) study, the I allele frequency shows a linear trend 
increase with running distance, hence aerobic ability; in Olympic standard runners of 
the distances <200m, 400-3000m, and >5000m, the respective I allele frequencies 
were 0.35, 0.53, and 0.62. On the other hand, the D allele has been associated with 
power-oriented performance, being found in excess in short-distance swimmers 
(Woods et al, 2001), power athletes (Nazarov et al, 2001), and as has been linlced with 
a greater strength gain in the quadriceps muscles during training (Folland et al, 2000).
It may appear that the I allele and II genotype may be of benefit in endurance events 
via its effects on the cardio-respiratory system. However, examination of the ACE 
genotype and VO2  max relationship has resulted in contradictory evidence, and while 
some investigators show as association (Hagberg et al, 1998), others do not (Rankinen 
et al, 2000a). Furthermore, even though the I/D polymorphism may play a role in an 
enhanced endurance performance, it is not mediated by differences in the cardio­
respiratory response to training (Woods et al, 2002).
In view of the fact that a physiological linlc between the ACE I/D polymoi'phism and 
‘endurance’ or ‘power’ performance is unlikely to involve the cardio-respiratory 
system, it is probable that an alternative lies at the skeletal muscle level. It has been 
stated that the tissue RAS metabolic involvement plays an important role in regulating 
human skeletal muscle and metabolism (Montgomery et al, 1999). Jones and Woods 
(2003) discuss how tlirough the existence of a functional renin-angiotensin system 
(RAS) in the skeletal muscles, raised ACE activity (DD genotype) will promote 
greater strength gains perhaps via muscle hypertrophy, although Sundgren et al (2003) 
showed an in vivo hyperplasia of cardiomyocytes after stimulation by Ang II. On the 
other hand lower ACE levels may promote enhanced endurance performance possibly
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via changes in substrate availability, muscle fiber type and efficiency. These findings 
suggest that the role of ACE I/D polymorphism can be of great importance beyond 
sporting activities, given the therapeutic treatments by means of ACE inhibitors; a 
pharmacological manipulation of this kind could benefit in muscular diseased states, 
such as congestive heart failure (Williams et al, 2000) as well as in other diseases 
causing low levels of O2 in the blood. To what extent endurance or power 
performance is dependent on the RAS at the muscle level, remains to be elucidated in 
future studies.
1.4.3 ACE I/D Polymorphism And Hypoxia
High altitude climbers demonstrate an association with the I allele. Elite British 
mountaineers, who had ascended over 7000m without the use supplemental oxygen, 
had a significant excess of the I allele and II genotype with respective frequencies of
0.7 and 0.48 (Montgomery et al, 1998). Of those climbers who had ascended over 
8000m without supplemental oxygen, none were of the DD genotype, while the top 
performer was of II the genotype. Even though this group sample is rather small to 
strongly support a gene association, it does suggest a performance advantage of the I 
allele at high altitude and more specifically in conditions of low oxygen.
In view of the fact that an increased arterial oxygen saturation (Sa02) is of benefit at 
high altitude, the RAS is probably of great importance. Ang II facilitates pulmonary 
vasoconstriction (Kiely et al, 1995), and high ACE activity is associated with an 
increased pulmonary hypertensive response in conditions of hypoxia (Kanazawa et al,
2000). It may therefore be speculated that a lower ACE activity will enable better 
oxygenation and more efficient alveolar ventilation during hypoxic conditions where 
supply of oxygen is scaice. Additionally, and as previously stated, the compensatory 
increase in alveolar ventilation also loiown as HVR, promotes an increase in arterial 
oxygen saturations and tissue oxygen delivery. In fact, II genotype is associated with 
an increased ventilatory response during hypoxic exercise (Patel et al, 2003).
43
Finally, the concept of a genetic advantage in those carrying the 1 allele in hypoxic 
conditions is further supported by a finding of better-preserved SaOi amongst those of 
the II rather than DD genotype during rapid ascent to altitude, Figure 1.8, but the 
absence of such when ascent is more gradual (Woods et al, 2002).
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Figure 1.7 Oxygen saturation at various altitudes by ACE genotype during the 1994 British Mount 
Everest Medical Expedition (rapid ascent group). The initial saturation on arrival at a higher altitude is 
shown. Sao2 with ascent was better sustained in the 11-allele subjects (W oods et al, 2002).
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1.4.4 ACE And AMS
Is it possible then that the ACE I/D polymorphism influences AMS? A speculation 
lies directly through alterations in blood volume and pressure by ACE elevation of 
Ang 11 levels, which would in turn, stimulate aldosterone production, leading to water 
and sodium retention. Individuals with AMS have been examined and found to retain 
more fluid and have increased plasma levels of aldosterone (Hackett et al, 1982; 
Bartsch et al, 1988). Given the role of the renin-angiotensin system in fluid retention, 
in addition to the ACE expression in the tissues of the lung, it may be possible that the 
DD genotype is associated with a higher prevalence of AMS.
It could be inferred that the 1 allele advantage at high altitude may mediate a reduced 
AMS occurrence. However, Dehnert et al, (2002) found no relationship between 
ACE genotype and AMS. A limitation of the study was that AMS assessment was 
made only a few hours after arrival at the tested altitude and no evidence of a better 
tolerance by any of the genotypes is available on the following day at altitude. As 
onset of AMS symptoms is considered, for most individuals, to begin between 6 and 
12 hours after arrival at altitude, concrete evidence of a specific ACE genotype and 
tolerance to AMS still remains unclear.
To date, no study has prospectively attempted to investigate the above. This is mainly 
due to cost of field studies as well as the need for a larger cohort in order to have a 
reliable association for a link between a genetic marker and a physiological response. 
It is one of this thesis’ aims to address AMS onset in a prospective study where the 
subjects would be tested upon arrival at altitude, and while their performance during 
further climbing would be monitored, they would be assessed again on their AMS 
status the following day.
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1.5 Aims Of Thesis
The aims of this thesis were to assess an innovative mountain rescue equipment, to 
observe performance of individuals whilst undergoing fast and slow ascents to 
altitude, and to investigate what role the ACE genotype plays in individual 
performance at high altitude. The aims were achieved through the following studies:
Study 1
To compare a mountain rescue casualty bag used by the Norwegian mountain rescue 
teams with a casualty bag currently used by the Scottish mountain rescue teams. This 
was achieved through the use of physiological and subjective responses of the 
participating subjects in each of the two bags.
Study 2
To compare the physiological responses of climbers assessed during a fast ascent 
altitude profile to the summit of Mont Blanc (4807m). Reference is given to those 
who became ill and were unable to perform under a hypoxic environment. 
Demographic information from the participating subjects was used in an attempt to 
explain the reasons for those who underperformed on the mountain. Furthermore, an 
investigation of the climbers’ ACE gene profiles was made to assess a possible 
genetic predisposition both in those who became ill and those who performed 
successfully.
Study 3
To compare the physiological responses during a slow ascent profile to 5000m in 
relation to the trekkers’ ACE gene profiles. Reference was also given to pre-exposure 
testing in an attempt to predict performance during exposure to altitude.
Study 4
To investigate the ACE genotype in those climbers who successfully summit Mount 
Everest (8850m).
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INTRODUCTION
Mountain rescue team call-outs occur frequently in the UK with over 800 emergency 
rescues each year (Hearns, 2000). During the period 1993 to 1995, there were 604 
incidents in the Scottish mountains in which 13% of the casualties became 
hypothermic, and 7% of hypothermic victims died (Scottish Mountaineering Journal, 
1993-1995). While casualties wait for rescue teams to arrive, they may encounter 
inclement weather including cold, wet and windy conditions. These harsh conditions 
may result in rapid body heat loss and lead to hypothermia in addition to the victims' 
injuries.
The first plan of action in the treatment of a hypothermic individual is to prevent 
further heat loss and to reduce the possibility of a hypothermic state. To achieve this, 
several casualty rescue bags and blanlcets have been developed. The effectiveness of 
such equipment has been studied in settings such as hospitals, laboratories and in the 
outdoors (Grieve, 1969; RAF Inst of Aviation, 1976; Light and Norman, 1980; Light 
et al, 1980; Bemier, 1988; Goodlock, 1995; Smith, 1996). While heat loss may be 
prevented using casualty bags, their insulating qualities will depend upon the 
environmental conditions. Criticism of some bags includes the fact that they are 
bulky, difficult to carry, and offer limited protection from the cold.
Anecdotal reports from Norwegian mountain rescue teams suggest that a single layer 
of bubble-wrap around the casualty may help prevent heat loss. Possible advantages 
of a bubble-wmp (BW) bag include its lightweight and low cost. However, there is 
no scientific evidence to substantiate the claim that a bubble-wrap bag is effective in 
preventing loss of body heat.
The aim of this study was to compare the BW bag against a standard casualty bag 
(CB) used by Scottish mountain rescue teams, in a cold (-10°C) and windy (wind 
speed 2.7 m-sec'^) environment using physiological and subjective responses of the 
participating subjects.
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METHODS
Subjects
Twelve healthy male volunteers (age 21 ± 1.3 years, body mass 71.9 ± 4.2 kg, body 
fat 12.7 ± 2.3%, height 1.77 ± .1 m) who were regular exercisers participated in the 
study. The subjects were hill-walkers, swimmers and canoeists and all had 
encountered cold conditions in the past, whether in the mountains, or the rivers and 
seas. Each subject completed a medical history and physical activity questionnaire. 
Subjects were informed about the nature, purpose and effects of the study before 
giving their wiitten consent to participate. They were asked to avoid consumption of 
alcohol and coffee for at least 12 hours prior to testing, and to report in a fasted state 
(overnight and morning) before each test. All subjects were randomly allocated into 
two groups. Half of the subjects were tested first using the CB and half were tested 
first using the BW. One week later the subjects crossed over to the other bag for 
testing. Ethics approval for the study was obtained from the University of Glasgow 
Ethics Committee.
Preliminary measurements
The following measurements were made: height (meters), body mass (kilograms), and 
body fat (%). Body fat was estimated at four sites (biceps, triceps, subscapular, and 
suprailliac) using the procedures outlined by Durnin and Womersley (1974).
Study Design
The experimental procedures for all the subjects were undertaken at the University of 
Glasgow Environmental Research Chamber. All trials were carried out between 8:00- 
10:00am to avoid any circadian rhytlim variations. Each subject underwent 2 
exposures in the environmental chamber while lying inside one of two bags: one in 
the standard mountain rescue CB, and one in the BW bag. Each exposure was 
plaimed to last 60 minutes. The exposures were at least one week apart to avoid any 
acclimatisation effects. After the equipment (thermistors) were attached to the 
subjects, they were dressed in the study clothing (see below). Thereafter resting 
measurements were taken. Resting (lying in a supine position) baseline measurements
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were made during a 10-minute period in an anteroom before the subjects entered the 
environmental chamber. The casualty bags were exposed and opened inside the 
chamber 10 minutes before the subject entered the chamber. When inside the 
chamber, the subjects lay in a supine position on a mountain rescue stretcher, and 
were placed inside the bag. The bag was then closed and sealed, and fans were turned 
on. The stretcher was at a height of 110 cm from the floor. Throughout both tests, 
skin and core temperatures were continuously monitored and recorded every 5 
minutes. Heart rate (every minute) and oxygen consumption (5 minute periods), 
subjective cold comfort and shivering (every 5 minutes) were measured throughout 
the test. At the end of the trial, the subjects were moved into a warm area (ambient 
temperature ~35®C) where blankets and warm drinks were provided. They were 
allowed to leave the laboratory only when their core temperature was above 36.0”C 
and rising.
Bags
Mountain Rescue Casualty Bag (Marshall bag)
The casualty bag (CB), Figure 2.1, consists of an outer shell constructed of 
neoprene/nylon material. This wind and waterproof outer shell wraps around an inner 
‘duffel’ bag. The subject lay on the inner layer, which was wrapped around him and 
secured, with Velcro strips. The outer layer was also wrapped around the subject and 
secured using straps attached the outer layer. A hood was attached to the rescue bag. 
The overall weight of the bag was 6.4 kg.
P
Figure 2.1 Casualty Bag
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Bubble-Wrap Bag
The bubble-wrap bag (BW), Figure 2.2, consisted of a single layer of bubble-wrap 
supplied by the company Sealed Air (New Jersey, USA). The BW was delivered by 
the company in roles BW; a prototype was designed according to the dimensions and 
make of the CB. The bubbles were ‘small’ as classified by the company, and 
measured 9.5mm in diameter and 4.2mm in height. The bubbles had a high-density 
polyethylene (HDPE) film laminated covering which enhanced puncture and tear 
strength. Once the subject was in position on the bubble-wrap, it was wrapped around 
him and held together with the use of elephant tape (sellotape). A hood, also made of 
bubble-wrap, was attached to the topside of the bag. The overall weight of the bag 
was 0.6 kg. 12 identical BW bags were made, one for each experimental trial.
Figure 2.2 BW bag during experimental trial (with subject permission).
The surface areas of the casualty and bubble-wrap bags were virtually the same. The 
surface area of the Bubble Wrap was 5.12m^ and the inner layer of the casualty bag 
was 5.13m^.
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Clothing
AU subjects in both experimental trials wore their own underpants. They all wore the 
same thermal underwear (leggings and long sleeved top), Ministry of Defence (MOD) 
issue kliaki trousers and zipped jacket (no hood) with draw strings, MOD issue kliaki 
hat with protective ear flaps and wool lining, MOD issue mitten gloves with wool 
inner lining, 2 pairs of wool socks and military boots.
Physiological Measurements
Heart rate was monitored using a PE3000 (Polar Vantage Kemple, Finland), and 
recorded every minute.
Four skin thermocouple wires (Comark Ltd, Hertfordshire, UK) were used for 
measurement of skin temperature at the chest, arm, thigh and calf; all attached to the 
skin with 3M micropore tape. The thermocouple wires were connected to a portable 
temperature logger (ICM 1242, Comark Ltd, Hertfordshire, UK), and values were 
recorded every 5 minutes. Mean weighted skin temperature was calculated as 
described by Ramanathan (1964),
M .T s k = 0 .3 tc h e s t  +  0 .3 ta rm  +  0-2tth igh  +  0 .2 t c a lf
Core temperature was measured with the use of a rectal probe (Mechanical workshop, 
University of Glasgow, Institute of Biomedical and Life Sciences), inserted 10 cm 
beyond the anal sphincter, comiected to the portable logger (KM 1242, Comark Ltd, 
Hertfordshire, UK) and recorded every five minutes, but monitored continuously.
Respiratory and metabolic measurements (Vs, Vo%) were made by means of open- 
circuit system spirometry in 5 minute intervals (at minutes 5-10, 15-20, 25-30, 35-40, 
45-50, 55-60) as the subject breathed atmospheric air and expired thi'ough a 
mouthpiece and hose into 150 L Douglas bags (polyurethane. Harvard Apparatus Ltd, 
Kent, UK). The Douglas bags were connected to the mouthpiece using a 2700 valve 
(Hans Rudolph), tubing and a 2100 3-way stopcock valve (Hans Rudolph). Gas 
analysis (02%, C02%) was earned out using an Oxygen Analyser (Servomex 570A, 
Crowborough, UK) and a Carbon Dioxide Analyser (PK Morgan Ltd, Rainhamm, 
UK). The gas analysers were calibrated before every test. Ve was measured using a
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Harvard dry-gas meter. V0 2  was calculated using University of Glasgow computer 
software.
Baseline measurements were taken in a room adjacent to the environmental chamber 
(ambient temperature -20°C), while the subjects lay quietly on an examination table 
for 10 minutes. They wore all their experimental clothing. Values were recorded for 
10 minutes and then averaged for the last 5 minutes for heart rate, skin and core 
temperature. Respiratory measurements were taken during the second 5 minutes of the 
10-minute period. Shivering and cold comfort scales were recorded at the end of 
baseline measurements.
Assessment o f  Cold Comfort and Shivering
Subjective comfort level responses were recorded every five minutes (from time 0 to 
60 minutes) using a Whole-Body Cold Comfort Scale (Table 2.2, page 67), and a 
Shivering Scale (Table 2.3, page 68). The subjects were shown the scale and asked to 
indicate perceived cold comfort and shivering states. The values for both scales were 
indicative of a whole body cold comfort and shivering, and not of specific body areas.
Environmental Chamber
The environmental conditions inside the chamber were: -10 °C + 1°C (dry bulb 
temperature) maintained using a Cool Guard Refrigeration Unit (C&M Refrigeration 
Ltd., Glasgow, UK) fitted with a cyclical thermostat. A continuous airflow at 2.7 
m-sec"  ^ (measured at feet of subjects) was provided by thi'ee Vent Axia (Vent Axia, 
Glasgow, UK) wall mounted fans. The wind chill index was estimated to be -17”C.
Termination o f Experiment
The criteria for termination of the trials were as follows:
1. subj ect ’ s voluntary withdrawal
2. subject’s core temperature reaching 35.5®C
3. completion of experimental procedure
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Statistical Analysis
A  Repeated Measures Analysis of Variance (ANOVA) was used to investigate the 
effects of bag, time, bag/time, order and subject effects. All variables were adjusted 
for baseline by subtracting each baseline from the respective score at each time point. 
In addition, Bonferroni multiple comparisons (with 95% Confidence Intervals) were 
carried out in order to provide an interval estimate of the true mean difference for 
those response variables where there was evidence of a significant difference between 
the bags. The shivering scale was reformulated. Originally the scale had a range of 0 
to 3, but 3 was never used and 2 only very sparingly. Therefore shivering was 
analysed using the following: no shivering corresponding to 0, and shivering which 
encompassed the scale numbers 1 and 2. The reconstituted Shivering variable (i.e. no 
shivering vs. shivering) was analysed using McNemar’s test for the data at 60 
minutes. Data in Figures 2.3A-1 IB are presented as median, 25% and 75% qualifies. 
Statistical significance was declared at P<0.05.
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RESULTS
Ali subjects completed the experimental procedures for both bags, as described in the 
Methods. Core temperature, skin temperatures (chest, thigh, triceps, calf), and heart 
rate have negative values (denoting a decrease from the baseline values), whereas 
oxygen consumption, cold comfort scale and perception of shivering have positive 
ones (denoting an increase from the baseline values). Figures 2.3A-12 give a visual 
representation of the changes in the tested measurements from baseline until 
termination of the experiment. Sample means, at thi'ee selected time points (20, 40, 
and 60 minutes) into the study are given in Table 2.3 together with the results of the 
corresponding Bonferroni follow-up multiple comparisons.
Core temperature
The core temperature increased from the baseline measurement between 0 and 5 
minutes for both bags. Thereafter, core temperature deereased tliroughout the tests 
(Figure 2.3A-B). There was no significant difference (p=0.57) in the decrease from 
baseline between the bags.
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Figure 2.3A Figure 2.3B
Box-plot showing the core temperature changes 
during exposure in the BW. Box-plot showing the core temperature changes 
during exposure in the CB,
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Mean skin temperature
The decrease in mean skin temperature was much greater in the BW compared with 
the CB (Figure 2.4A-B). The 95% Cl shows that on average the BW mean skin 
temperature was significantly lower (p<0.005) than the CB with the BW being 
between 3.9°C to 5.2°C lower than the CB at 60 minutes.
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Figure 2.4A
Box-plot showing the mean skin temperature changes 
during exposure in the BW.
Figure 2.4B
Box-plot showing the mean skin temperature changes 
during exposure in the CB.
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Individual skin site temperatures
The skin temperature decrease in all four sites tested (chest, arm, thigh, and calf) was 
significantly greater (p<0.005) in the BW compared with the CB. At 60 minutes the 
temperatures for all sites in the BW were lower than in the CB by: 3.7 °C to 6.4 *^C for 
the triceps (Figure 2.5A-B), 3.5 °C to 5.4 °C for the chest (Figure 2.6A-B), 3.4 °C to
5.3 °C for the thigh (Figure 2.7A-B), and 3.1 °C to 5.1 ^C for the calf (Figure 2.8A-B).
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Figure 2.5A
Box-plot showing the triceps temperature changes 
during exposure in the BW.
Figure 2.5B
Box-plot showing the triceps skin temperature changes 
during exposure in the CB.
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Figure 2.6A
Box-plot showing the pectoral temperature changes 
during exposure in the BW.
Figure 2.6B
Box-plot showing the pectoral temperature changes 
during exposure in the CB.
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Figure 2.7A
Box-plot showing the thigh temperature changes 
during exposure in the BW.
Figure 2.7B
Box-plot showing the thigh temperature changes 
during exposure in the CB.
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Figure 2.8A
Box-plot showing the calf temperature changes 
during exposure in the BW.
Figure 2.8B
Box-plot showing the calf temperature changes 
during exposure in the CB.
Heart rate
There was a general decrease in heart rate for both bags until the latter stages of the 
tests when both bags showed an increase (Figure 2.9A-B). There was no significant 
difference (p=0.98) between the bags.
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Figure 2.9A
Box-plot showing the heart rate changes 
during exposme in the BW.
Figure 2.9B
Box-plot showing the heart rate changes 
during exposure in the CB.
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Oxygen consumption
There was a trend for V0 2  to rise in both bags over time (Figure 2.10A-B), while there 
was a tendency for V0 2  in the BW to be higher than the CB. There was no significant 
difference (p=0.12) between the bags.
V 0 2  
C h a n g e s  f rom Basel i ne
Bubble-wrap
2
1
0
0  5 10 15 20  25  30 35 40  45  50 55 60
Casual ty Bag
2
1
0
0 5 10 15 20 25 30  35  40  45 50 55  60
Time (Minutes) Time (Minutes)
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Box-plot showing the V O  3  changes 
during exposure in the BW. Box-plot showing the V O  3 changes 
during exposure in the CB.
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Cold comfort
For CB, the median score did not rise after 35 minutes whereas there was a fairly 
regular rise in cold comfort throughout the test (Figure 2.11A-B). The cold comfort 
score in the BW was significantly higher (p<0.005) than in the CB. The 95% Cl, at 60 
minutes for the BW was higher than the CB by 0.7 to 3.3 units.
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Figure 2.11 A
Box-plot showing the cold comfort changes 
during exposure in the BW.
Figure 2.11B
Box-plot showing the cold comfort changes 
during exposure in the CB.
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Shivering
Shivering was analysed in terms o f reported shivering (yes or no). By 15 minutes, 
none o f the 12 subjects were shivering in the CB while two subjects were shivering in 
the BW. By 30 minutes, 1 person was shivering in the CB and 5 were in the BW, 
(Figure 2.12). At 60 minutes, 3 out o f the 12 shivered in neither bag, 3 shivered in 
both, and, most importantly, 6 shivered in BW but not in the CB (p= 0.02).
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Figure 2.12
Graph showing the shivering status of subjects by group.
Order o f testing
A significant effect was observed for the order by which the trials took place, BW 
first or CB first. The first test tended to generate more marked responses (increases or 
decreases) than the second test; for core temperature p=0.03, for mean skin 
temperature p<0.005, for Vo^ p<0.005, and for cold comfort p<0.005.
62
Sample mean differences and 95% confidence intervals (shown in brackets) for the 
selected variables of Core Temperature, Mean Skin Temperature, Heart Rate, Oxygen 
Consumption, and Cold Comfort of each bag at three selected time points (20, 40, and 
60 minutes) into the study, are presented in Table 2.1.
Variable Material
Time
20 minutes 40 minutes 60 minutes
Core Temperature 
(°C)
BW 0.075 -0.233 -0.408
CB -0.017 -0.158 -0.233
95%CI ( ~ 0 . 1 8 , 0 . 3 6 } ( - 0 . 3 1 , 0 . 1 6 ) ( - 0 . 4 2 , 0 . 0 7 )
Mean Skin 
Temperature
CC)
BW -4.53 -5.54 -6.18
CB -1.36 -1.51 -1.63
95% C l ( ~ 3 .  7 , - 2 .  7) ( - 4 . 7,  - 3 . 4 ) ( - 5 . 2 ,  - 3 .  9)
Heart Rate 
(beats, min'^)
BW -1.42 -3.42 -0.75
CB -2.33 -2.42 -2.92
95% C l ( - 4 . 1 ,  5 . 9 ) ( - 5 . 3 ,  3 . 3 ) ( - 4 . 3 ,  8 . 7 )
V O ,
(m l.kg\m in^)
BW 0.253 0.253 0.973
CB 0.191 0.218 0.415
95% C l ( - 0 . 4 8 , 0 .  60) ( - 0 . 5 2 , 0 . 5 9 ) ( - 0 . 1 1 , 1 . 2 3 )
Cold Comfort (0-10 
unit scale)
BW 2.17 3.25 4.42
CB 1 . 0 0 1.83 2.42
95% Cl ( 0 . 1 ,  2 . 3 ) ( 0 . 1 ,  2 . 8 ) ( 0 . 7 ,  3 . 3 )
Table 2.1 Sample mean differences and 95% confidence intervals. (The values have been calculated  
as follows: Bubble Wrap minus Casualty Bag differences o f  changes from  baseline).
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DISCUSSION
The major finding of this study was that the bubble-wrap bag (BW) did not protect the 
subjects as effectively as the casualty bag (CB) under the selected environmental 
conditions o f-1 0 ”C ambient temperature and wind speed of 2.7m-sec"\ The four 
individual skin sites and mean skin temperature were lower for the BW. Cold 
comfort scores (i.e. subjects felt colder) and perception of shivering were higher for 
the BW compared with the CB.
There was no difference for core temperature between the bags. The subjects 
defended the decrease in core temperature in both bags by vasoconstriction in order to 
increase insulation (Toner and McArdle, 1988). However, it is likely there was 
greater vasoconstriction in the BW. Evidence for this comes from the greater 
decrease in skin temperature for the BW in all four sites (triceps, calf, chest and thigh) 
and the mean skin temperature compared with the CB (Table 2.1). With the CB, the 
much higher skin temperatures demonstrated that there was a significantly smaller 
decrease in skin temperatures. It is speculated that the insulation of the BW material 
is less than that of the CB, resulting in lower skin temperatures. As the skin 
temperatures were much lower in the BW, it seems plausible to suggest that, had the 
conditions been harsher or the experiment lasted longer, it is likely that the core 
temperature in the BW would have become lower than the CB. In both bags, the core 
temperature showed a slight rise in temperatui'e at the start of the trials, (Figures 2.3 A 
and 2.3B). The initial increase in core temperature was most likely due to the initial 
vasoconstriction and redistribution of blood to the core. It may be attributed to a time 
lag in measurement through the use of a rectal thermistor (Lloyd, 1986) and the 
possible warming effect of a fairly long period (15 min) in a warm anteroom while 
wearing the protective clothing.
While there was no significant difference in oxygen consumption (V0 2 ) between the 
bags, there was a tendency for V0 2  to increase more in the BW compared with the CB 
(Table 2.1, and Figures 2.10A & 2.1 OB). A fall in skin temperature is associated with 
the onset of shivering (lampietro et al, 1960). Thus, it is to be expected that the lower 
mean skin temperature for the BW would initiate shivering sooner than the CB. The 
core temperatures in both bags were very similar but the mean skin temperature at 60
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minutes in the BW was much lower than the CB, 28.2®C vs. 31.1“C, and was well 
below the uniform cutaneous temperature of 29.0^C, at which shivering begins 
(Mercer, 1991). Based on the mean skin temperature at 60 minutes, it is to be 
expected that shivering intensity would be greater in the BW. While there was no 
significant difference in VO, between the BW and the CB, the subjects perceived that 
they were shivering much more in the BW than in the CB. By 60 minutes, hi the CB, 
2 out of 12 subjects were shivering compaied with 9 out of 12 in the BW, (Figure 
2.12). Although the subjects did ‘shiver’ more in the BW, this was not reflected in 
their V o, values as they did not differ significantly between the bags. Errors on gas 
collection or analysis are unlikely to have occurred, as all equipment were checked 
and calibrated prior to every trial.
There were no differences for heart rate (HR) between the CB and the BW, (Table 
2.1). There was a general trend for HR to decrease in the first half of the tests. 
Possible contributory factors for the decrease in HR included the supine position of 
the subjects, peripheral vasoconstriction and cooling of the face (Le Blanc et al, 
1976). The adoption of a supine position would enhance baroreflex sensitivity and 
result in a decreased HR (Vander, 1994). A greater central volume and increased 
central venous pressure would result from cold induced sympathetic vasoconstriction. 
The enhanced ventricular filling and larger end-diastolic volume results in a greater 
stroke volume. Consequently the HR is reduced to maintain a constant cardiac output 
(Graham, 1988). Cooling of the face has been associated with an increase in 
parasympathetic activity and a resulting decrease in HR (Smith, 1996). There was a 
trend for HR to increase in the second half of the tests particularly with the BW in the 
last 10 minutes. This increase may be attributed to shivering (Haymes and Wells, 
1986).
The perception of cold increased in both bags, the increase being significantly higher 
in the BW (Figures 2.11 A & 2.1 IB and Table 2.1). A drop in skin temperature is 
probably the signal for cold sensation (Toner and McArdle, 1988). Thus, it may not be 
unexpected that the lower mean skin temperature in the BW resulted in a greater 
perception of cold.
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There was a significant effect in the order of which the trials took place, regardless of 
which bag was used first. The first test tended to produce more marked responses 
(increases or decreases) in the measurements than the second test. This may be due to 
a slight acclimatization effect that may have taken place (Leppaluoto et al, 2001). 
These findings highlight the need for an order effect to be considered in the design of 
similar studies.
There were a number of possible sources of heat loss in this study. The face was 
directly exposed to a continuous airflow produced by the fans. Most subjects reported 
that they had a cold face. Respiratory heat loss in a cold enviromnent has been shown 
to account for around 8% of total body heat loss (Doubt, 1991). Some subjects 
reported that their feet were eold and some experieneed a tingly-cold sensation 
primai’ily in their big toes. In almost all the BW trials heat loss took place in the chest, 
triceps, thigh, and calf areas as evidenced by a fall in skin temperature at these sites. 
The most mai'ked decrease in skin temperature between the BW and the CB was at the 
triceps. It is speculated that this may have been due to contact with the stretcher’s 
metal rail, whieh induced conductive heat loss.
It would be appropriate to emphasize the fact that the BW, although had the same 
surface area as the CB, its weight was 1/10^ *' that of the CB. It was important to test 
the BW the exact way it is used by the Norwegian teams in their rescue missions, and 
not add on a second or third layer in an attempt to standardize bulkiness or weight.
In conclusion the BW bag was found to be less effective compared to the CB in 
protecting subjects under the imposed enviromnental conditions. This was evidenced 
by significantly lower skin temperatures (mean and individual skin sites), an increased 
feeling of cold, as well as a higher perception of shivering in the BW compared to the 
CB. This study demonstrated that the Casualty Bag offers more protection from cold 
and wind than the Bubble-Wrap.
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Table 2.2
Whole-Body Cold Comfort Scale
0-Comfortable
1-
2-Slightly Cold
3-
4-Fairly Cold
5-
6-Moderately Cold
7-
8-Very Cold
9-
10-Unbearable
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Table 2.3
Shivering Scale
0-Absence of Shivering
1-Slight Shivering
2-Moderate Shivering
3-Severe Shivering
CHAPTER 3A
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INTRODUCTION
Many sea level dwellers venture to altitude to climb high mountains including the 
highest peak in Western Europe, Mont Blanc, 4807m. Anecdotal evidence from 
Alpine guides indicates that a considerable number (-30%) of those who aspire to 
reach the Mont Blanc summit fail to do so mainly as a result of the adverse effects of 
hypoxia. This fairly high failure rate may not be too suiprising as the literature 
highlights that exercise at altitude results in a decreased physical work capacity with a 
fall of around 30% of V0 2  max at 4000m compared with sea level values (Buskirk et 
al, 1967). In addition, acute mountain sickness (AMS) is a common characteristic at 
altitudes >2500 m (Hackett and Roach, 2000) and has been shown to have an 
incidence of over 50% at 4300 m (Hackett et al, 1976). Monitoring subject responses 
to altitude may, along with subject characteristics, allow the identification of poor 
responders to a hypoxic environment and, for such subjects, precautions could be 
taken to avoid problems at altitude.
A number of variables may be predictive of success at altitude including recent 
altitude history of the individuals. Altitude acclimatisation is considered to be an 
important factor for ‘success’ at altitude and is strongly linked to ventilatory 
acclimatisation. A brisk hypoxic ventilatory response (HVR) is considered to be 
advantageous as it leads to an enhanced arterial oxygen saturation (Sa0 2 ), and has 
been associated with less severe AMS (King and Robinson, 1972; Sutton et al, 1976; 
Hackett et al, 1982), although this in not observed at all times. In addition, an 
increased hypoxemia has been shown in those with AMS and has been associated 
with hypoventilation (Anliolm et al, 1979; Hackett et al, 1982; Moore et al, 1986) and 
impaired gas exchange (Ki*onenberg et al, 1971; Sutton et al, 1976).
The aim of the study was to assess performance (i.e. success/failure and time to 
summit if successful) on the ascent of Mont Blanc (4807m) based on subject 
characteristics, recent climbing history and physiological variables measured at the 
Gouter Hut (3817m) before and after an attempted ascent on the Mont Blanc summit.
70
METHODS
Subjects
Between the 14^ "^ -19^  ^ of August 2002, 285 subjects (49 females [35+11 years]; and 
236 males [28+12 years]) who visited the Gouter Hut, Figure 3A.1, prior to an 
attempted ascent of the Mont Blanc summit volunteered to take part in the study. A 
small number of subjects refused to be tested as they felt unwell. Subjects taking 
acetazolamide or steroids (used in AMS prevention/treatment) were excluded from 
the time of the study. Of the 285 subjects, 199 were tested on two occasions, before 
and after the attempt to the summit. The remaining 86 subjects did not report back to 
us at the Gouter Hut for various reasons. Some descended by another route and some 
did not want to delay their descent by being tested at the Gouter Hut. Some subjects 
provided summit information by post or e-mail at a later date. Thus, summit success 
or failure information was available from 216 subjects. Ethics permission was 
granted from the Glasgow University Ethics Committee and informed consent was 
obtained from all volunteers.
Figure 3A.1 Gouter Hut, 3817m.
71
Study Design
The normal ascent route starts in from the Chamonix valley (1100m), and includes 
and overnight stay at the Gouter hut (3817m) on Day 1, and thence to the summit 
(4807m) and back to the hut on Day 2. The experimental procedures took place in the 
Gouter Hut (3817m), France. The subjects were tested on the day of arrival at the hut 
(Day 1) and the following day (Day 2) once they had attempted to reach the Mont 
Blanc summit (4807m), if  their descent route was via the Gouter Hut. An attempt was 
made to make sure that all subjects were tested after they had been in the hut and 
rested for at least one hour. For all the pre-summit testing this aim was successful, 
whereas for the post-summit testing it was not possible to comply rigidly with this 
guideline as some climbers were pressed for time and did not want to wait 30 minutes 
before being tested. Nevertheless, all climbers were tested upon arrival at the hut 
from their descent and had at least 20 minutes of rest before testing. A subject 
information questionnaire and an AMS questionnaire were completed and 
physiological variables were measured before and after the summit attempt.
Questionnaires
On the first day the subjects completed a questioimaire (Appendix B) which included 
questions on age, nationality, gender, smoking status, previous altitude experience, 
residing altitude, climbing profile over the past 14 days prior to the study, and route to 
the Gouter Hut. On return to the hut the next day (after the attempted ascent on the 
summit) the subjects completed a questionnaire, which included ascent and descent 
information. Documentation was provided in four languages: English, French, Italian, 
and German.
Physiological measurements
Partial pressure end tidal carbon dioxide, (PETCOg), arterial oxygen saturation 
(SaOi), heart rate (HR), and respiratory rate (RR) were measured. All measurements 
were made using a capnograph (Nellcor Eden NPB75, Puritan-Bennett, Bicester, UK).
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Physiological Tests - Procedures
The subjects sat quietly for about 6 minutes, Figure 3A. 2. They were asked to not 
talk or fidget. They breathed atmospheric air through a mask with a line (Nellcor 
Eden) attached on the expirate side, which was connected to the capnograph for 
analysis. The saturation probe was attached on the right index finger. Values were 
recorded when they were stable (around 4-6 minutes). ‘High’ and ‘low’ readings 
were recorded for all measurements and the averages were subsequently used in the 
analysis of the results.
Figure 3A.2 Collection o f  physiological measurements in Gouter Hut (with subject permission).
AMS assessment
AMS scores for Days 1 and 2 were obtained using the self-assessment section of the 
Lake Louise consensus on AMS scoring (Roach et al, 1993). As suggested, a score of 
4 and above was used to define the presence of AMS (Maggiorini et al, 1998).
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Statistical Analysis
Logistic regression and Classifieation Trees (Aitchison et al, 1995) were used to 
investigate which, if any, variables were predictive of a suecessful ascent of Mont 
Blanc. Logistic Regression was also used to investigate which, if any, variables were 
able to predict the presence of AMS (on reaching the height of the Gouter Hut). The 
potential predictive variables considered in these analyses were: the pre-summit 
‘average’ values for PETCO2 , SaOz, HR, RR and the subject characteristics obtained 
from the questionnaires (i.e. smoking status, gender, age, sleeping and climbing 
profiles over the past 14 days before this ascent). Both the raw AMS score and the 
presence/absence of AMS were included in the success/failure to climb Mont Blanc 
analysis.
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RESULTS
Eighteen subjects failed to reach the summit. Of these 18, 6 turned back to support 
their friends who were unable to continue. Thus, only 12 elimbers, out of a total of 
210, did not reach the summit as a result of altitude problems on the way to the 
summit. For these 210 subjects, Table 3A.1 presents summary statistics of the 
physiological variables broken down by the Ascent Outcome (i.e. did or did not reach 
summit). For those categorised as having AMS, only 2 out of 27 (7%) failed to reach 
the summit as opposed to 10 out of 183 (5%) who failed amongst those without AMS.
Failed to Reach 
Summit (n=12)
Successfully Reached 
Summit (n=^198)
PETCO2 (mttiHg) 34.5 (3.0) 33.0 (5.2)
Sa02 (%) 86.5 (3.9) 87.3 (5.1)
HR (beats.mitd) 99.7 (8.2) 91.1 (12.6)
RR (breaths.min'h 13.7 (5.3) 12.7(4.6)
AM S Score 2 (0-7) 1 (0-7)
Table 3A.1 Sample means and standard deviations (SD) by summit ‘outcome’ for ‘average values’ o f  
physiological variables taken at Gouter Hut before attempt on the summit: end tidal carbon dioxide 
(PETCOa), arterial oxygen saturation (SaOa), heart rate (HR), respiratoi-y rate (RR) and acute mountain 
sickness (AMS) score.
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Logistic regression shows that only the Climbing Profile over the previous 14 days 
significantly (p=0.04) affected the Ascent Outcome (i.e. whether or not a subject 
successfully climbed Mont Blanc from the Gouter Hut) although Heart Rate both 
individually (p=0.06) and having corrected for climbing profile (p=0.07) did get very 
close to inclusion in the final model. The effect of climbing profile is illustrated in 
Table 3A.2 where one can see that those who had climbed over 4000m in the previous 
14 days had a significant advantage in terms of a successful ascent of Mont Blanc. All 
subjects who had been to 4000m in the previous 14 days made a successful ascent of 
Mont Blanc. Although not statistically significant, the slightly higher number of 
subjects who failed to reach the summit for those who had climbed between 3000 and 
4000m in the previous 14 days, as opposed to those who had climbed less than 
3000m, is likely to be simply due to sampling variability.
Climbing Profile in Previous 14 
Days
Failed to Reach 
Summit (n-12)
Successfully Reached 
Summit (n=198)
Less than 3000m 5 68
Between 3000 and 4000m 7 65
Over 4000m 0 65
Table 3A.2 Climbing Profile in previous 14 days by ascent ‘outcome’ o f Mont Blanc from the Gouter 
Hut (i.e. maximum altitude reached in previous 14 days).
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A Classification Tree for the Ascent Outcome based on these data is provided in 
Figure 3A.3 and illustrates again the dominating effect of climbing profile. However, 
Classification Trees allow the investigation of ‘high order interactions’ not often 
investigated nor easily identified by Logistic Regression and here this technique 
highlights the effect of heart rate already suggested by Logistic Regression and indeed 
uncovers an additional effect of PETCO2 . This analysis allows one to deduce that 
those climbers likely to fail to reach the summit of Mont Blanc from the Gouter Hut 
are those with a Heart Rate in excess of 85 bpm and a PETCO2 of more than 36 
mmHg and who have not climbed higher than 4000m in the previous 14 days.
Climbed more than 4000m  
in the last 14 days?
NO
!
i
Was the clim ber’s PETCO2 
greater than 36 mmHg ?
i
W as the clim ber’s H R. 65 successes
less than 85 b.p.m. ? 0 failures
37 successesNO 0 failures
Y m 68 successes
11 failures
28 successesNO 1 failure
Figure 3A 3 Classification Tree for the Ascent Outcome o f Mont Blanc from the Gouter Hut for the 
2 1 0  subjects.
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For i\xQ Ascent Times (hours) o f the 198 successful climbers o f Mont Blanc (from the 
Gouter Hut), various linear model variable selection procedures (such as Forward 
Stepwise and Best Subsets) indicated that the Climbing Profile in the previous 14 
days was the key significant (p<0.01) factor. The sample mean ±  SD ascent time for 
those who had been over 4000m in the previous 14 days was 4.03 + 0.7 hours, for 
those between 3000 and 4000m it was 4.27 + 0.9 hours and for those below 3000m it 
was 4.47 ±_ 0.8 hours. Further, the Age o f the (successful) climber appeared to be 
marginally significant in addition to Climbing Profile (p=0.08). However, as can be 
seen from Figure 3A.4 where ‘smooth non-parametric regression’ fits o f the effect of 
Age on Ascent Time for the three sub-groups o f Climbing Profile (i.e. <3000m, 3000 
to 4000m and >4000m in the previous 14 days) are presented, it appears that the 
relationship o f Age and Climbing Profile on Ascent Time is not so straightforward or 
indeed linear and/or additive! This notion is confirmed and amplified using a 
Regression Tree approach whose results are illustrated in Figure 3A.5. Here the 
effects o f Age, Climbing Profile and Sex o f the (successful) climber on Ascent Time 
o f Mont Blanc (from the Gouter Hut) and conform to ‘conventional wisdom’ with 
older climbers the slowest and younger climbers with recent time spent at altitude the 
fastest.
Scatterplot of Ascent Time vs Age
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B  a  B >4000m
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Figure 3A 4 Non-Parametric Regressions on Age for the Ascent Time o f Mont Blanc from the Gouter 
Hut by level o f Climbing Profile in the previous 14 days (197 subjects).
78
Regression Tree for Ascent Time of Mont Blanc
Yes
Yes
Yes
Yes
No
No
No
No
Was  the climber Female?
Was the climber aged 
over 57 years?
4.57 (0 80) hrs 
23 Subjects
4.42 (0,79) hrs 
54 Subjects
4.05 (0.84) hrs 
46 Subjects
5.21 (0 88) hrs 
11 Subjects
3.97 (0.64) hrs 
60 Subjects
Had the Qimber been over 
4000m in previous 14 days?
Had the Qimber been over 
3000m in previous 14 days?
Sample Mean (s.d ) hrs 
Number of Subjects
Figure 3A S Regression Tree for the Ascent Time o f Mont Blanc from the Gouter Hut for the 197 
subjects.
Those who had been over 4000m had a higher SaO] and lower raw AMS score than 
those who had not been above 3000m in the previous 14 days (Table 3A.3). Similarly 
the AMS scores on Day 2 were significantly different between those who had been 
over 4000m (2.6+2.0 units) compared with those under 3000m (4.7+2.7 units). With 
respect to presence or absence of AMS (i.e. an AMS score of 4 or more) on ascent to 
the Gouter Hut, a Logistic Regression showed that the Climbing Profile again proved 
significant (p=0.03) with the Age of the climber verging on being additionally useful 
(p=0.07). The effect of Age was that increasing age decreased the probability of 
AMS. This analysis was based on the 285 climbers whose physiological 
measurements were taken at the Gouter Hut of whom 40 had AMS and 245 did not.
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Climbing Profile in previous 14 days
Less than 3000m 
(n=73)
Between 3000 
and 4000m 
(n-72)
Over 4000m 
(n=65)
PETCO2 (mmHg) 33.1 (5.2) 32.7 (4.7) 33.5 (5.4)
Sa02(%) 86.0* (5.9) 87.6 (4.7) 88.1 (4.1)
HR (beats.min^) 93.3 (11.4) 91.5 (12.6) 89.6 (13.7)
RR (brths.mitt^) 13.2 (4.2) 12.4 (4.7) 12.6 (5.1)
AM S Score (units) 2* (0-7) 1.5 (0-7) 1 (0-6)
Table 3A.3 Summary statistics o f  PETCO2 , Sa02, HR, RR, and AMS Score for Day 1 by Climbing 
Profile in previous 14 days.
Sample mean (SD for all variables apart from AMS.) - sample median (range) for AMS 
*Significantly different from over 4000m
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There was no strong indication that the presence or absence of AMS (or indeed the 
raw AMS score) was of any value in predicting the Ascent Outcome of climbers 
(Table 3A.4) especially if one adjusts for Climbing Profile in the previous 14 days nor 
indeed that the 75 climbers whose final Ascent Outcome was unknown (or turned 
back to support fellow climbers) had a significantly higher percentage of AMS than 
those whose outcome was laiown (Chi-Square Test, p=0.69).
A M S No A M S
Ascent Outcome (n=^40) (n=245)
Failed to reach summit 2 10
Reached summit 25 173
Unknown etc. 13 62
Table 3A.4 Relationship o f  presence/absence o f  AMS (i.e. a raw AMS score o f 4 or more 
corresponds to presence o f AMS) to Ascent Outcome.
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The relationship between the raw AMS scores before and after the attempted ascent of 
Mont Blanc from the Gouter Hut is illustrated in the scatter plots of Figure 3A.6 
where it appears that there is, at best, a limited relationship between the AMS scores 
before and after the attempted ascent which hardly differs between those whose ascent 
was successful and those ascent was not. Indeed, a two-sample t-test of the 
difference in raw AMS score (after -  before) shows no significant difference (p = 
0.13) between the two ascent outcomes.
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Figure 3A.6 Plots o f raw AMS scores before and after attempted ascent o f  Mont Blanc from the 
Gouter Hut labelled by Ascent Outcome (plots also include the line o f equality o f  AMS before and 
after ascent).
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As can be seen in Figure 3A.7 there are no meaningful relationships among any of the 
respiratory variables (viz. PETCO2 , SaOz, HR and RR) -  although some have very 
small sample correlations significantly different from zero - nor indeed of any of these 
with the raw AMS score taken on arrival at the Gouter Hut. Similarly, there are no 
worthwhile relationships to be reported after return from the attempted ascent on the 
summit.
Matrix Plot of AMS Before,  PETC02, S a 0 2 ,  HR, RR
AMS B afora
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Figure 3A.7 Pair-wise plots o f  all physiological variables and AMS score taken at arrival at Gouter 
Hut
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DISCUSSION
Climbing Profile over the previous 14 days significantly affected the ascent outcome 
and ascent times (Table 3A.2). It is not unexpected that recent exposure to over 
4000m would confer an advantage for those who wished to ascend a 4800m peak. A 
recent study by Muza et al (2004) showed that a 12-day period at 4300m resulted in 
an increase in Sa02 from 84% on Day 1 to 89% on Day 12. Minute ventilation 
increased over the same time period from 11.6 to 16.0 Imiin'^ (Muza et al, 2004). 
Thus it may have been anticipated that differences in recent exposure to a range of 
altitudes would have resulted in physiological differences in the subjects in the 
present study. Table 3 A. 3 shows that those who had been over 4000m in the previous 
14 days had a higher SaOz and lower AMS raw score than those who had not been 
above 3000m. The slightly higher SaOz for those who had been over 4000m may have 
resulted in an advantage during the ascent of Mont Blanc. Those who had been over 
4000m in the previous 14 days made the fastest ascent and none of the climbers in this 
group failed to reach the summit. It may have been expected that the PETCO2 in this 
group would have been lower (the Sa0 2  was higher in this group) than those in the 
under 3000m group as lower values would indicate an increase in alveolar ventilation 
resulting from a hypoxic stimulus. However, there were no differences for PETCO2 .
For those who had not been to 4000m in the previous 14 days, the classification tree 
identified two other factors, which had a bearing on ascent outcome, namely heart rate 
and PETCO2 . The higher heart rates (> 85 beats-min'*) of those who failed may be 
may be reflective of an increased sub-maximal cardiac output in an attempt to cope 
with the hypoxic conditions (Stenberg et al, 1966), but also a reflection of the 
increased sympathetic activity during high altitude exposure (Malhoita et al, 1976). 
Altitude acclimatisation is associated with an increase in ventilation. With ventilatory 
acclimatisation, the increase in alveolar ventilation would result in a decreased 
PETCO2 . Thus, it may not be suiprising that the PETCO2 has been included as a 
factor in the classification tree. In those subjects who had not been to 4000m in the 
previous 14 days and who had heart rates over 85 beats-min'^ 11 out of the 12 failures 
had a PETCO2 of 32 mmHg or above.
Summit times become slower as the age of the climber increased and are slower for 
females. These findings are not surprising as maximal oxygen uptake (V0 2  max), a
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measure of cardio-respiratory endurance, has been shown to decrease with age with a 
gradual decline in V0 2  max from around the age of 20 years. Astrand and Rodahi 
(1986) give a representative example of this decline when they state that 65 year olds 
will have a V0 2  max of ~ 70% of that of a 20 year old. V0 2  max in females has been 
found to be, on average around 65 to 75% of that of men (Astrand and Rodahi, 1986).
Although the Classification and Regression Trees are suggestive of significant and 
interesting effects of various variables, especially Climbing Profile, on the ability to 
complete the ascent of Mont Blanc and, indeed the time to do so, a further study of 
performance on this or on a comparable mountain must be canied out to test the 
predictive capability of these models. One must assess any predictive model, whether 
simple linear regression or Trees-based models, on a further set of comparable data in 
order to make justifiable scientific claims.
AMS was significantly lower in those with recent exposure to 4000m+. It is to be 
expected that recent exposure to altitude would lower the incidence of AMS and 
enhance performance in a hypoxic enviromnent (Lyons et al, 1995; Schneider et al, 
2002). Whether subjects were classified as having AMS or based on the raw AMS 
score, there was no evidence of any relationship of either of these with summit 
success or indeed with the ascent time. The incidence of AMS in this study at 3817m 
was 14% on Day 1 and 46% on Day 2. Another study at a similar altitude to ours, 
3650m, in the Swiss Alps (Maggiorini et al, 1990) reported an incidence of AMS of 
8%. The incidences seen in this study (14% before the summit attempt and 46% after) 
almost fall within the range of 12-42% from a number of studies assessed at altitudes 
below 4000m (Hackett et al, 1979; Houston et al, 1985; Montgomery et al; 1989; 
Honigman et al, 1993). Even though not all the above studies used the exact same 
scoring system, they all assessed their subjects using similar guidelines to evaluate 
their AMS symptoms. Possible reasons for an increase in AMS from Day 1 to Day 2 
may be attributed to the increased length of time at a higher altitude as the climbers 
went to and from the Mont Blanc summit. The onset of AMS symptoms is considered 
to begin between 6 and 12 hours after arrival at altitude (Ward et al, 2000). Most 
subjects started to climb to the Gouter Hut from 2300m, with an ascent time of 5-6 
hours. Thus, the fact that some subjects were tested fairly soon after they had entered
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the Gouter Hut may have been too early to detect AMS symptoms in some of them. 
Recommendations for the treatment of AMS emphasise that AMS subjects should not 
climb higher. Thus it is not suiprising that the AMS scores increased as climbers 
went higher and were involved in strenuous exercise (Roach et al, 1998). The great 
increase in AMS incidence in this study from 14% on Day 1 to 46% on Day 2 is not 
unexpected as the subjects were at altitude for longer and most of them climbed to 
4800m. The finding that AMS incidence is lower in ‘older’ subjects supports the 
statement by Roach et al (1995) that the incidence of AMS decreases in ‘older’ 
subjects.
There was a poor relationship between the physiological variables and AMS. These 
findings disagree with studies that have shown that a low SaOi is associated with 
subsequent development of AMS (Roach et al, 2000; Hussain et al, 2001). The link 
between the severity of mountain illness and hypoxemia has been attributed to 
hypoventilation (Anholni et al, 1979; Hackett et al, 1982; Moore et al, 1986) and 
impaired gas exchange (Ki’onenberg et al, 1971; Sutton et al, 1976). There were no 
significant differences in PETCO2 between the AMS and non-AMS subjects before 
the ascent and suggests that hypoventilation is unlikely to be the cause of the AMS.
One subject upon amval at the Gouter hut on Day 1 had a Sa02 value of 62%. The 
subject’s PETCO2 was 43mmHg, and he was classified as AMS asymptomatic. The 
low Sa0 2  value was questioned by the experimenters but repeat measurements using 
another capnograph verified the initial readings. A physician examined the subject 
and observed central cyanosis. It was speculated that the subject suffered from a 
cardiac problem. Based on the low Sa02, the experimenters considered that the 
subject would be unlikely to reach the summit. However, the subject did reach the 
summit of Mont Blanc in 5.5 hours. He was advised to seek medical advice as soon 
as possible.
The 6%, n=12 (or 8%, n^l8), failure rate is much lower than the estimated 30% 
failure rate of the Alpine guides’ predictions. However, 24% of our tested climbers 
never reported back to us and these missing data may hide the fact that the failure rate 
was in fact higher than we recorded. It is possible that the 69 subjects who did not 
provide summit information failed to do so because they were unsuccessful. This
86
speculation is unlikely to be valid for some subjects as they descended Mont Blanc by 
an easterly route and thus did not descend via the Gouter Hut to be tested. There were 
no differences for any of the measurements tested on Day 1 between those who were 
tested on both occasions (Days 1 and 2) and the 69 who were not tested on Day 2.
In conclusion, climbing profile over the previous 14 days significantly affected the 
ascent outcome and ascent times. Previous recent exposure to an altitude of over 
4000m resulted in faster ascent times, higher SaO? and lower AMS scores than those 
who had not been above 3000m in the previous 14 days. Recent exposure to over 
4000m confers an advantage to those who wish to ascend a 4800m peak.
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INTRODUCTION
As a component of the circulating (endocrine) renin-angiotensin system (RAS), 
angiotensin-converting enzyme (ACE) cleaves vasodilator kinins whilst yielding 
vasoconstrictor angiotensin (which also drives salt and water retention through 
stimulation of aldosterone release). However, paracrine RAS also exist in human 
tissues (Yosipiv et al, 1994; Danser et al, 1995; Reneland et al, 1999) where they play 
diverse roles. A variation of the human ACE gene has been identified, in which the 
presence (insertion, or I-allele) rather than the absence (deletion, D-allele) of an extra 
287-base pair fragment is associated with lower circulating (Rigat et al, 1990) and 
tissue (Costerousse et al, 1993; Danser et al, 1995) ACE activity.
An excess frequency of the ACE I  allele has been noted amongst elite endurance 
athletes (Gayagay et al, 1998; Myerson et al, 1999; Woods et al, 2002, Tsianos et al, 
2004) which might be partly explained by a genotype-dependent improvement in 
skeletal muscle mechanical efficiency with training (Williams et al, 2000). The 
substantially greater I-allele excess reported amongst high altitude (HA) mountaineers 
(Montgomery et al, 1998) thus might relate to ‘positive’ self-selection by success in 
physical performance (increased metabolic efficiency- the ratio of internal energy 
consumed per unit energy output) being an especial advantage in the hypoxic 
environment. Such ‘positive’ selection might also relate to better-sustained arterial 
oxygen saturations being associated with the /-allele (Woods et al, 2002). 
Alternatively, this association might relate to ‘negative’ selection of individuals less 
prone to the debilitating symptoms of acute mountain sickness (AMS).
To date, no study has ‘prospectively’ addressed the possible association of ACE 
genotype with successful HA ascent. Meanwhile, only one (negative) study has so far 
examined the association of ACE genotype with AMS development (Dehnert et al, 
2002). The aims of this study were: to address the relationship between ACE 
genotype with AMS onset on both, andval to altitude and consequent return from a 
higher altitude, to investigate any I allele benefits with altitude performance (assessed 
by successful or not attempt to the summit of Mont Blanc), and look for any 
differences in the tested physiological measurements between the ACE genotypes.
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METHODS
The study was approved by the Glasgow University Ethics Committee. Written 
informed consent was obtained from all volunteers.
Subjects
Consecutive Caucasian climbers attempting to climb Mont Blanc by the ‘normal’ 
route were approached over a nine-day period (Aug 14-22, 2002), and 284 
consequently participated. This route entails ascent from the Chamonix valley 
(1100m) to the Gouter hut (3817m) on Day 1, and thence to the summit (4807m) and 
back to the hut on Day 2. Subjects taking acetazolamide or steroids (used in AMS 
prevention/treatment) were excluded from the time of the study. From those who 
consented to take part, a buccal swab was obtained for future genetic analysis. 
Physiological measurements (PETCO2 , SaO], HR, RR) and AMS scores were 
recorded. Those who chose to descend via the same route were again assessed on day 
2, when AMS scores were recorded, and success or failure in summiting was 
ascertained.
AMS Score Assessment
AMS scores for Days 1 and 2 were obtained using the self-assessment section of the 
Lake Louise consensus on AMS scoring (Roach et al, 1993). As previously assessed, 
a score of 4 and above was used to define the presence of AMS (Maggiorini et al, 
1998).
Genotyping
Buccal cells were collected using Whatman sterile foam tipped applicators (Whatman 
Bioscience Ltd, Abington, Cambridge, U.K.) swabbed vigorously against both inner 
cheeks and dampened under the tongue. The swabs were then pressed firmly onto a 
Whatman FT A micro-card (Whatman Bioscience Ltd, Abington, Cambridge, U.K). 
From these, DNA was extracted, and ACE genotype determined at a separate site 
(UCL), using a tlnee-primer method as previously described (O'Dell et al, 1995).
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Statistical Analysis
Differences in physiological parameters between genotypes were assessed by one­
way ANOVA, or Kruskal-Wallis where appropriate. Genotype-dependent differences 
in AMS prevalence and success in reaching the summit were considered via chi- 
squared tests. Statistical significance was set at p<0.05.
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RESULTS
Of 1223 eligible subjects on Day 1, 284 agreed to participate. Their genotype 
distribution (II 56 [19.7%], ID 142 [50%], DD 86 [30.3%], I allele frequency = 0.45) 
was consistent with Hai'dy-Weinberg equilibrium. Of these, 210 descended by the 
same route on Day 2. Their Day 1 physical and physiological characteristics, AMS 
onset and severity, and genotype distribution (II 43 [20.5%], ID 107[51%], DD 
60[28.5%]) did not differ significantly (p=0.81) from those unavailable for 
reassessment. These subjects descended by another route or failed to report back.
Geîwîype and Success in Reaching Summit
Success in reaching the summit was dependent upon ACE genotype. Of those subjects 
returning by the same route, I allele frequency for those who reached the summit was 
0.47 compared to 0.21 for those who did not reach the summit (p=0.01), with 53 
[88.3%] of DD genotype reaching the summit, compared to 102 [95.3%] of those of 
ID genotype, and all 43 [100%] of those of II genotype (p=0.048). Figure 3B.1. 
Summiting offers a greater variety of descent routes: those who summit are thus more 
likely to descend by an alternative route than those who fail, who will generally 
descend by the same route. Even if we assume that all the 74 taking an alternative 
route of descent had successfully summited, the ACE I-allele remains significantly 
associated with success (I-allele frequency 0.46 that all those taking an alternative 
route of descent versus 0.21 for success vs. failure groups, p=0.02). Only if one 
assumes that all those taking and alternative route of descent had failed to summit (an 
implausible claim, for reasons explained above) does this association weaken (I-allele 
frequency 0.47 versus 0.40 for success vs. failure groups, p=0.10; for those 
successful, p=0.25). To consider the possibility whether success to the summit was 
genotype dependent based on climbing profile (i.e. <3000m, 3000 to 4000m and 
>4000m in the previous 14 days) the genotype frequency distribution in the most 
successful group to the summit ( >4000m) was 21 II (23%), 48 ID (54%), 21 DD 
(23%).
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Figure 3B.1 Graph showing percentage o f  subjects successful in reaching the summ it o f  Mont Blanc 
for each ACE 1/D genotype. Success for those returning by the same route was dependent upon ACE 
genotype.
AMS incidence and severity
On Day 1, 40 (of 284) individuals were suffering from AMS. The percentage AMS 
incidence by genotype was 21.4% [12/56] for the II, 7.0% [10/142] for the ID, and 
20.9% [18/86] for the DD, (p=0.003) for comparison o f genotype distribution 
between those with and without symptoms the, ID group having a significant lower 
incidence. On Day 2, 92 (of 200) individuals satisfied the diagnostic criteria for 
AMS. The percentage AMS incidence by genotype was 48.8% [20/41] for the II, 
40.6% [41/101] for the ID and 53.7% [31/58] for the DD group, (p=0.3) for 
comparison o f genotype distribution between those with and without symptoms. 
Ordered logistic regression showed an association between genotype and AMS 
severity on Day 1 (p=0.045) in favour o f the ID genotype, and no association for Day 
2 AMS sufferers (p=0.08). In addition, there was no statistical evidence to suggest 
that Day 1 AMS sufferers were less likely to be successful in reaching the summit 
(p=0.25).
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Finally, there were no significant differences between the genotypes and the recorded 
physiological measurements (PETCO2 , SaÛ2 , HR, and RR) on Day 1 or 2, Tables 
3B.1 and 3B.2.
DD ID II
SaOi (%) 86.9+ 5 88.2+ 5 87.6+5
FETC02(mmFIg) 33.1+5 32.7+ 5 33.3+ 6
Heart Rate (beats.min “') 92+13 91.9±13 91.2+12
Respiratory Rate (breaths.min “ )^ 13.1+5 12.4±5 12.9+4
Table 3B.1 Physiological variables data on Day 1 according to ACE genotype.
DD ID II
Sa02(%) 88.1+5 87.8± 8 85.5±5
PETCO2  (mmHg) 32.7+ 5 33.2+55 34.1+5
Heart Rate (beats#min “ )^ 94.5±12 92.6+13 93.7±11
Respiratory Rate (breaths.min " )^ 15.4+6 14.1+6 14.9+6
Table 3B.2 Physiological variables data on Day 2 according to ACE genotype.
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DISCUSSION
The ACE I-allele is associated with success in HA ascent in this, the first prospective 
study to address this question. Such a finding is consistent with the previously 
reported excess frequency of the I-allele amongst elite mountaineers (Montgomery et 
al, 1998). This association however, seems unrelated to AMS incidence or severity. 
The overall incidence of AMS on Day 1 in this study was 14% and agrees with 
reports from other studies at similar altitudes in the Alps (Maggiorini et al, 1990; 
Maggiorini et al, 1998), and such incidence (and severity) were umelated to ACE 
genotype. The association of AMS with genotype on Day 1 seemingly relates to a 
biologically-implausible heterozygote advantage which, itself, camiot account for the 
genotype-association noted with ascent success.
Thus, the ACE I-allele is associated with a greater likelihood of ascent to a 4800m 
summit, and this success seems umelated to a genotype association with AMS 
development. Such data support those of Dehnert (Delinert et al, 2002) who similarly 
found no association of ACE genotype with AMS amongst alpine mountaineers.
No significant differences were observed between the genotypes and PETCO2 , Sa02, 
HR, or RR. It was hypothesised that there would be a difference between Sa02 and 
genotype in view of the fact that Woods et al, (2002) showed that subjects of the II 
genotype had higher SaOi values, but his results were measured over the span of 12 
days at altitude.
Further studies are required to explore the physiological mechanisms underlying this 
observed association. A genotype-dependence in metabolic/mechanical efficiency of 
skeletal muscle may partly contribute (Woods et al, 2002). Equally, a better 
maintained Sa02 has been previously found amongst I-allele subjects during a rapid 
ascent to altitude (Woods et al, 2002), a phenomenon which may relate to genotype- 
dependent differences in hypoxic exertional ventilatory response (Patel et al, 2003), 
and which may contribute to improved HA performance (Montgomery et al, 1998). 
Finally, higher ACE activity, as marked by the DD genotype, has been associated 
with exaggerated hypoxic pulmonary vasoconstriction (Cargill and Lipworth, 1996), 
and possibly thus with increased ventilation-perfusion mismatch (Hlastala et al, 
2004).
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In conclusion, it was shown that performance at high altitude is associated with ACE 
I/D genotype, but this does not appear to be due to an effect on the onset or severity of 
AMS, or associated with any of the measured physiological variables.
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INTRODUCTION
A number of factors influence performance at high altitude (HA). Determination of 
those variables associated with HA problems may help identify those individuals who 
experience difficulties. Consequently, strategies to prevent HA problems may be 
used for those susceptible to HA.
The ACE gene’s I-allele association with endurance performance (Gayagay et ai, 
1998, Myerson et al, 1999, Tsianos et al, 2004) and the ability to attain higher 
altitudes (Montgomery et al, 1998), are both of importance in HA performance. The 
mechanisms however underlying this benefit of the I-allele are not yet fully 
understood. A significant genetic influence for increased arterial oxygen saturation 
(Sa02) levels exists in HA residents (Beall et al, 1994), A better maintained Sa02 has 
been reported amongst II genotype subjects who undertook a rapid ascent to altitude, 
as opposed to no genotype differences when ascent was gradual (Woods et al, 2002). 
Furthermore, an excess of the I-allele has been observed in highland natives living 
over 3000m (Rupert et al, 1999), as well as in HA mountaineers (Montgomery et al, 
1988). Despite the positive I-allele associations, Dehnert et al, (2002) and this thesis 
(Chapter SB, Tsianos et al, 2004b) reported that no ACE genotype related differences 
exist for the onset of AMS on ascent to altitude.
The hypoxic ventilatory response (HVR) is also of importance at HA as it aids in the 
maintenance of increased Sa0 2  levels, with a large response resulting in higher 
oxygen saturations, leading to a better climbing performance (Schoene et al, 1984). 
Although a brisk HVR may be a factor in predicting onset of Acute Mountain 
Sickness at altitude (King and Robinson, 1972; Moore et al, 1976), some studies show 
no such relationship (Milledge et al, 1988; Milledge et al, 1991). Patel et al, (2003) 
showed the ventilatory response during hypoxic exeiiion to be genotype related, with 
those of the II genotype exhibiting a larger increase in minute ventilation. No 
information is however available on what role the degree of HVR may play on 
predicting any other physiological measurements.
Previous studies have been characterized by information by small subject numbers. 
Consequently the findings from those studies may have limitations. There is a need to 
increase the knowledge base and further explore the current I-allele associations. The
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aims of this study were to investigate the role of the ACE genotype on SaOi, HR and 
AMS during gradual ascent to altitude (5000m). Furthermore, the degree of HVR, 
measured during rest at sea level, was used to predict the physiological responses 
tlu’ough the daily measurements of SaOi, HR, and AMS, while any ACE genotype 
related differences on HVR were also considered.
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METHODS
Subjects
The subjects, Caucasian, (n=55, 33 males [36+12 years]; 22 females [32+6 years]), 
members of a research expedition to Nepal, volunteered for the study. The expedition 
was organised by Medical Expeditions (MEDEX). All participants where divided into 
5 separate trekking groups, and followed the same route. Table 4.1 (page 111) on their 
way to the research Base Camp (BC) (5000m), Figure 4.1. Ethics permission was 
granted from the Joint University College London Ethics Committee, and informed 
consent was obtained from all volunteers.
Figure 4.1 Research/Chamlang Base Camp, 5000m.
Design
HVR was measured at sea level during rest, and was assessed 2 months prior to the 
expedition. Genetic samples were collected and ACE genotype identification was 
subsequently made at UCL cardiovascular genetics laboratory.
Recording of all physiological measurements (AMS, SaO], HR) took place daily in 
the Nepalese Himalayas during the trek from Tumlingtar (330m) to the Chamlang BC 
(5000m) in the Hungu valley, as well as for the 3 days after arrival at BC.
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ACE Genotyping
5ml single venous blood sample was drawn from each subject and ACE genotype was 
determined using a thiee-primer method (O’Dell et al, 1995). All DNA samples were 
numbered, and not named. No database contains names as well as genotype data. All 
DNA samples were analysed at a separate site (UCL), blinded to subject data.
Hypoxic Ventilatory Response (HVR)
The hypoxic ventilatory response was assessed thiough the method of progressive 
hypoxia and isocapnia, as previously described (Rebuck and Campbell, 1974). A 
rolling seal spirometer (Morgan Spiroflow, Model #131, PK Morgan, Gillingham, 
Kent, England) was used with a turbine providing a circulation of gas round a closed 
circuit. No absorbent was put into the soda lime canister but an external absorber was 
provided with a tap and bypass so that expired CO2  could be absorbed or not. This 
allowed the operator to maintain the PETCO2 constant on the carbon dioxide analyser 
(Carbon Dioxide, PK Morgan LTD, Rainham, Kent, England). The PETCO2 , 
ventilation, and SaOb were monitored via a pulse oxymeter (Pulse Oxymeter 515A, 
Novametrix, Medical Systems Inc.) and recorded on line using the computer program 
software “Spike 2”. From these measurements, minute ventilation against Sa02 could 
be plotted and the A Vent/A SaC^ subsequently calculated (L-%Sa02"^).
HVR Protocol
The subject was made comfortable in a semi-reclined resting position; a mouthpiece 
and nose-clip were put on and the subject breathed room air (Figure 4.2). A 
saturation probe was attached on the subject’s right index finger. The spirometer was 
opened to the air, and when filled with 6L for >70kg subject or 5L for <70kg subject, 
it was then connected to the breathing apparatus. When the PETCO2  values became 
steady, the subject was connected to the spirometer at the end of expiration. PETCO2  
was kept at starting values by manipulating the bypass tap. As the decreasing Sa02 
values reached 80% the experimental procedure was then terminated by turning the 
mouthpiece tap to air. Consequent establishment of HVR was made thi’ough analysis 
of traces on the “Spike 2” program, using a breath-by-breath data analysis.
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1Figure 4.2 HVR assessment (with subject permission).
Measurements in the Himalayas 
Physiological Measurements (SaOx HR)
The measurements were made daily in the morning, while the subjects were sitting at 
rest for at least 30 minutes, in a quiet warm environment, and prior to a meal. A pulse 
oxymeter (Nonin Onyx DE/089) was used for the recording of the data. ‘High’ and 
‘low’ values were recorded for the measurements of SaO] and HR, while the average 
was used in the data analysis.
Acute Mountain Sickness (AMS)
AMS was measured daily in the morning, using the AMS self-assessment section of 
the Lake Louise consensus on AMS scoring (Roach et al, 1993). The symptoms 
tested were: headache, gastrointestinal, tiredness, dizziness, and quality of sleep; the 
scoring scale for each symptom ranged from 0-3. A combined score of 4 and above 
denoted AMS, as previously described and recommended (Maggiorini et al, 1998).
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Statistical Analysis
Statistical analysis was conducted using STATA (v 8.0, College Station, Texas) 
unless otherwise stated. SaOi and HR are presented as means and standard deviations, 
whereas AMS was measured on an ordinal scale. Differences in both SaCb and HR 
by ACE genotype over altitude were considered using SAS procedure mixed model, 
hence considering all repeated measui'es from all individuals, and a spatial correlation 
structure was applied to account for the altitudes being unevenly spaced to account 
for differences in height achieved from day to day. Differences in AMS by ACE 
genotype over altitude, were considered using generalised estimating equations, in 
which, AMS was categorized into a binary variable, <4 and >=4, as <4 defined ‘no 
AMS’ and > -4  defied ‘AMS’; the percentage of individuals with AMS is presented 
by ACE genotype over altitude. Linear regression analysis was used to examine the 
effect of HVR on the change in SaO] and HR over altitude. To consider whether HVR 
differed by ACE genotype analysis of variance (ANOVA) was conducted. Statistical 
significance was set at p<0.05.
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RESULTS
Hypoxic Ventilatory Response
HVR was assessed in 44 of the subjects. HVR values ranged from 0.14 -  2.38 
L/SaOi. There were no significant differences in HVR by ACE genotype (DD=0.54 + 
0.32 L/SaOz, ID=0.57 ± 0.39 L/SaOs, II-0.56 ± 0.12 L/SaOs), p=0.98.
No significant linear relationship was observed for the HVR effect on daily mean 
SaOi, p=0.37, (Figure 4.3) and neither was its effect significant on HR and AMS, 
p>0.05.
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Figure 4.3 Relationship between mean SaO^ vs. HVR.
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Daily Physiological Measurements
Of the participating subjects, 45 subjects agreed to have their genotype information 
identified. The genotype distribution was: DD=19, ID=21, 11=5. Genotype 
distribution was not in Hardy-Weinberg Equilibrium, DD [42.2 %], ID [46.7 %], II 
[11.1 %]; I allele frequency is 0.34.
Overall, there is a borderline significance for the differences in SaC^ changes over 
altitude according to ACE genotype (p=0.04). Figure 4.4 shows that the II group had 
relatively lower mean SaOb for approximately half of the altitudes. The values were 
very similar at lower altitudes, and as the altitude increases, the difference between 
the II group and the two others (DD, ID) broadens, values being lower for the IPs. If 
the 3 days at BC are included in the analysis, then the overall difference becomes a 
non-significant one, p=0.07.
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Figure 4.4 Graph showing mean oxygen saturation (Sa0 2  %) by altitude according to ACE genotype.
(DD n=20, ID n=21, II n=6 ).
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A closer look into the data analysis, and more specifically on the percentage change in 
the daily SaOi from one altitude to the other, revealed that the only significant SaO] 
change between ACE genotypes, was the one between the altitudes of 4835m to 
5000m, p=0.44. Figure 4.5.
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Figure 4.5 p values for differences in percentage change in daily SaO] by ACE genotype between 
Changes in altitude.
X  axis values: I=change between I”' and 2"  ^ altitude change, 2=change between 2"^  and 3’''^  altitude 
change, ... 14=change between 14'  ^and 15'  ^altitude change.
Red line denotes the p =  0.05 significance level.
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Figure 4.6 shows the mean HR by altitude and ACE genotype. Although mean values 
in the II group were higher, there were no significant HR differences by altitude and 
ACE genotype, p-value 0.99. The same was true for the daily AMS onset, with 
altitude change. There were no differences in AMS incidence by altitude and ACE 
genotype, p>0.05. Figure 4.7.
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Figure 4.6 Graph o f mean (and SD) HR (beats.min‘') by altitude (m) and ACE genotype.
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Figure 4.7 Graph o f  percentage o f those having AMS, split by ACE genotype, over the 18 
changes in altitude (m) (including the days at BC).
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DISCUSSION
The finding that the II genotype may be associated with a lower SaOz during a trek 
from 330 to 5000m is contrary to a previous study (Woods et al, 2002), which 
reported genotype-dependent alterations in SaOi in which the II genotype resulted in 
higher Sa02. The finding in the present study however, is questioned. While a 
statistical significant difference was found, there is some doubt as to the physiological 
significance of this finding. In the Woods et al (2002) study, a ‘rapid’ and a ‘slow’ 
group ascended to approximately 5000m, in an average of 12 and 18.5 days 
respectively. Sa02 values were independent of the ACE genotype and remained so 
for the slow ascent group, in whom the fall in Sa0 2  with ascent did not differ amongst 
genotypes. However, Sa02 in the rapid ascent group was significantly higher for those 
subjects with a II genotype (p=0.01). The present study investigated a group whose 
ascent profile to 5000m was ‘slow’, requiring an average of 19-21 days to arrive at 
BC. There were no differences between any of the genotypes for the daily Sa02, 
except for the last change in altitude before arrival to BC, a change of less than 150m, 
4835m to 5000m, although, the overall statistical significance suggests that the II’s 
have lower Sa02 values. Although, there is an overall significance in the paiticular 
results, the physiological meaning of the magnitude of this difference is very small. 
The most likely explanatory reason for such an observation in the last change in 
altitude, is speculated be have arisen from the very small number of II subjects in the 
present study, 5 II vs. 19 DD vs. 21 ID. The small number of II’s in the group may 
not have been truly representative for what actually happens at altitude in II genotype 
subjects, during this particular ascent profile. Furthermore, the ascent rate is of 
importance in the ways certain physiological changes will occur. Woods et al (2002) 
showed a better maintained Sa02 for the II subjects whose ascent profile was rapid 
(12 days). The lack of an effect of the ACE genotype on Sa02 during a slower ascent, 
an average of 18.5 days in the Woods et al (2002) study and 19-20 in the present one, 
is probably a reflection of the reduced influence of ACE activity. This difference 
between rapid and slow ascents is likely to be due to the short-lived (as low as 12 
days) beneficial effects of the RAS at altitude associated with the I-allele (Milledge et 
al, 1983).
HR at HA increases as a reflection of an increased sympathetic drive and also due to a 
higher cardiac output (during the first week) in response to the reduced oxygen
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content in arterial blood (Stenberg et al, 1966), as well as due to dehydration resulting 
in a reduced stroke volume (SV) (Ward et al, 2000). In the present study a HR 
increase in the group is indeed observed with altitude, but this difference is not 
significant between ACE genotypes. Wood’s HR and ACE genotype unpublished 
data on the same groups from his work on ACE genotype and SaOi (Woods et al, 
2002) also showed no genotype differences in both slow and fast ascent groups 
(Woods, personal communication).
As the I-allele is associated with decreased levels of ACE, this allows for natriuresis 
and diuresis, both beneficial adaptations to altitude, aiding in reduced formation of 
edemas, whose increased fluid retention for the D-allele could contribute to Acute 
Mountain Sickness (Bartsch et al, 1991). However, an ACE genotype dependence for 
AMS onset with daily changes in altitude was not observed, in agreement with a 
previous report (Dehnert et al, 2002), as well as with the results obtained in Chapter 
3B of this thesis. Although the ascent profiles in the Delinert et al, (2002) and 
Chapter 3B studies were very rapid ones (an average of 3 days to reach 4559m and 
3817m respectively), it is unlikely that a slower ascent, an average of 19-21 days in 
this study, would have changed the findings. During a slower ascent profile, 
individuals acclimatize more efficiently and are less likely to succumb to AMS 
symptoms (Ward et al, 2000).
The reflexive increase in ventilation induced by hypoxia, the hypoxic ventilatory 
response, may aid in an improved performance at altitude. The finding that HVR 
cannot predict AMS susceptibility at high altitude agrees with previous such reports 
(Milledge et al 1988; Milledge et al, 1991; Bartsch et al, 2002). However, an 
enhanced ability to respond faster to the hypoxic condition would allow for better- 
maintained SaOi levels (Schoene et al, 1984). This was not was confirmed here in 
that those subjects with a brisk HVR did not have higher SaOi values during the trek 
compared to those with a slow HVR. Patel et al. (2003) on the other hand, showed an 
ACE genotype related advantage during acute exertional hypoxia in which those 
subjects with the II genotype exhibited a larger increase in minute ventilation, which 
may account for the increased SaOi levels found in the fast ascent profile subjects by 
Woods et al (2002). In both latter studies exposure to hypoxia, was either acute or 
fast. The present study did not show a genotype selective benefit on HVR. The HVR
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measurements in this study were made at rest, whereas in the Patel et al, (2003) study 
measurements were made during sub-maximal exercise, which may have instigated a 
greater hypoxic response accounting for the observed genotype differences. It is 
likely that the slow ascent profile in this study may have acclimatized the subjects 
sufficiently, and why no relationship was observed between HVR and SaOz.
In conclusion, although a borderline significant result was obtained suggesting overall 
lower SaOi values for the II genotype, its true physiological significance is 
questioned. Further, no genotype related differences were seen for either HR or AMS. 
There were no differences in HVR by ACE genotype, and no association effects for 
the speed of the HVR response were observed on daily Sa02, HR or AMS values. 
ACE genotype appears to have a greater influence on performance when 
acclimatisation time has been limited or when hypoxic exposure is acute, and as the 
present group underwent a ‘slow’ ascent profile, the non-significant genotype related 
results are likely to have been due to this, and also possibly the very low number of 
IPs in the group.
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Place Altitude (m)
Tumlingtar 330
Kartighat 410
Ghote 645
Phedi 1415
Guranse 2820
Gadel 1820
Kiraunle 2610
Basmir 2750
Nusa 2910
Zetra Kola 3160
Kothe 3560
Tagnay 4290
Khare 4895
Triffm 4770
Base Camp 5000
Base Camp oayi 5000
Base Camp oayz 5000
Base Camp oays 5000
Table 4.1. Trekking Schedule by Altitude
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CHAPTER 5
ACE
Oynd'H<>U4^ Ever'eitClCmbery, 8850m/
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INTRODUCTION
Mountaineers aspire to climb to the highest mountain on earth, Mount Everest, at 
8850m. However, there is no existing systematic investigation on why some fail or 
succeed. Since the first recorded expedition to Mount Everest in 1922 until 2002, 
there have been 175 deaths, and at least 1655 summit successes; a ratio of 1:10, the 
worst year in 1996 had a ratio of 1:6.5. A number of possible factors that may 
influence summit success in climbing are acclimatization, weather conditions, use of 
supplementary oxygen, physical endurance, or even one’s individual physiology to 
name a few. One variable, which may have a bearing in performance on Everest, is 
the ACE genotype.
The I-allele version of the ACE gene is well known for its associations with beneficial 
physiological responses in hypoxic conditions (Montgomery et al, 1998; Woods et al, 
2002; Patel et al, 2003; Tsianos et al, 2005). To date, no other study has investigated 
summit success and a possible association with genotype. This study set out to 
describe the ACE genotype in a number of climbers who attempted to climb Mount 
Everest and to relate ACE genotype in those successful summiteers.
113
METHODS
The study had institutional ethics committee approval (UCL), and written informed 
consent was obtained from all volunteers.
Subjects: High altitude mountaineers (n=64, 58 males [36+ 8.8 years] 6 females 
[33.1+ 4.6 years]) were recruited from both Mt Everest base camps (5200m) North 
side-Tibet and South side-Nepal, prior to an attempted ascent to the summit (8850m), 
in the spring of 2004.
Genotyping: Buccal cells were collected using Whatman sterile foam tipped 
applicators (Whatman Bioscience Ltd, Abington, Cambridge, U.K.) swabbed 
vigorously against both inner cheeks and dampened under the tongue. The swabs 
were then pressed fiimly onto a Whatman ETA micro-cai'd (Whatman Bioscience Ltd, 
Abington, Cambridge, U.K). From these, DNA was extracted, and ACE genotype 
determined using a three-primer method as previously described (O'Dell et al, 1995).
Statistical analysis:
Descriptive analysis was performed for the group as a whole, those who succeeded, 
and those who failed. Chi-squared analysis was used to determine any differences in 
genotype distribution between the two groups.
114
RESULTS
Genotype distribution for the entire group (n=64) was: 14 DD [22%], 32 ID [50 %], 
18 II [28%]; I allele frequency 0.53, and was consistent with Hardy-Weinberg 
Equilibrium. Genotype distribution in those who succeeded (n=42) was: 10 DD 
[24%], 22 ID [52%], 10 II [24%]; I allele frequency 0.50 (Figure 5.1), and in those 
who failed (n=22) was 4 DD [22 %], 10 ID [53%], 8 II [25%]; I allele frequency 0.59. 
There were no genotype differences between successful and failed climbers, p=0.56. 
For Caucasians alone (n=53), genotype distribution in those successful (n=36) was: 8 
DD [22 %], 19 ID [53%], 9 II [25%]; I allele frequency 0.51, and in those who failed 
(n=17) was: 4 DD [24 %], 7 ID [41%], 6 II [35%]; allele frequency 0.56. There were 
no genotype differences between successful and failed climbers, p=0.69.
55 40
□ DD genotype 
I ID genotype 
■ II genotype
Figure 5.1 ACE genotype distribution amongst successful summiteers (n=42), I-allele frequency 0.50, 
p=0.56.
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DISCUSSION
Previous studies have suggested a selective advantage for those with the II genotype 
at HA. The results of the present study do not support such findings. Instead, an 
exactly equal allele frequency was found in those who reached the most hypoxic point 
on the surface of this earth. There are a few speculations for this observation. 
Montgomery et al, (1998) reported that amongst 25 British mountaineers who had 
ascended beyond 7000m without the use of supplementary oxygen, a significant 
excess of the I allele and II genotype was demonstrated. Amongst the 15 climbers 
who had ascended beyond 8000m without supplementary oxygen, none was of the 
DD genotype (6 II and 9 ID), and when ranked by the number of such ascents, the top 
performer was of the II genotype. This is a very small group for a genotype- 
performance association, nevertheless, an allele skew amongst high altitude 
mountaineers was demonstrated. The possibility that Montgomery’s et al, (1998) 
findings are a coincidence in favour of the I-allele and II genotype could be attractive, 
but may not be realistic.
The successful climbers in the present study, indeed, successfully ascended Everest at 
8850m, but all used supplementary oxygen. All of Montgomery’s climbers had 
ascents without the use of supplementary oxygen above 7000m, and more than half 
above 8000m. The use of supplementary oxygen at extreme altitudes is of 
physiological (West et al, 1983a) as well as psychological assistance (Everest 
summiteers personal communication). It is possible that a genotype selective 
disadvantage at extreme altitudes may have been masked thi'ough the use of such 
ergogenic aid, as this enhances performance. The use of oxygen in essence 
eliminated to a degree the severe hypoxia, which may otherwise induce genotype 
related effects such as pulmonary vasoconstriction and its subsequent maladies.
Acute versus chronic exposure to altitude is a likely explanatory reason for the present 
findings and the differences between Montgomery’s study. A characteristic in the 
mountaineers studied by Montgomery et al, (1998) was their ability for rapid ascends 
on high mountains (Montgomery personal communication). It was previously shown 
in this thesis (Chapter 3B) that those climbers with an II genotype were significantly 
more successful (none failed) during a rapid ascent to the summit of Mont Blanc 
(4807m); an altitude not as extreme to the ones being discussed here, but nevertheless
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high enough to cause many of hypoxia’s ill effects on the body if attained rapidly. 
Patel et al, (2003) showed an II advantage for minute ventilation, in which those 
subjects with the II genotype had higher ventilations during acute experimental 
exposure to hypoxia; a response beneficial for maintaining SaOi levels a high as 
possible. Increased arterial oxygen saturations have been shown to be crucial for 
high altitude performance (Schoene et al, 1984), and Woods et al, (2002) 
demonstrated an II advantage for higher daily SaOi in those climbers undertaking a 
rapid ascent schedule to altitude. Milledge et al, (1983) however, clearly showed that 
any RAS benefits at altitude aie rather short lived (I2-20days), and as time progresses 
any advantages from the effects of a particular ACE genotype (II in this case) 
disappear. Woods et al, (2002) and this thesis (Chapter 4) both confirm the latter 
suggestions and showed that physiological responses during staged and slow ascents 
to HA do not differ amongst subjects of the 3 ACE genotypes. On the other hand 
though, exposure to altitude in those climbers who attempt to summit Mount Everest 
is clironic. Three to four weeks are required to arrive at BC (5200m) in order to 
successfully acclimatize, and another three to four weeks at higher elevations for 
preparatory climbing, establishing high altitude camps, and resting, before a potential 
summit attempt.
It could be suggested that the II genotype is of benefit for moimtaineers during rapid 
and acute exposure to hypoxia, whereas when exposure is slower and chronic, all 
genotypes appear to behave similarly. For the purposes of attempting the summit of 
Mount Everest, it would seem rather doubtful that ACE genotype plays a major role 
during such slow ascent profile to HA. However, it is likely that once at extreme 
altitudes, comparable to ones in the ‘death zone’ (above 8000m), the ability of the 
human body to utilize more efficiently the scarce amounts of oxygen, which most 
likely includes genotype-dependent differences in substrate selection, metabolic 
efficiency, and muscle fibre type (Jones and Woods, 2003), may well be depended on 
ACE genotype. It is probable that slow and chronic exposure to hypoxia, along with 
use of supplementary oxygen, could both compensate for any disadvantages that the 
most likely D-allele carriers would otherwise experience. The predominant factor in 
many studies showing an II genotype advantage during acute exposure to hypoxia, 
rapid ascent profiles, or ascents to very high altitudes, appears to be the hypoxic 
response. Thus, removing to a large extent the stressor of severe hypoxia via the use
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of supplementary oxygen, any beneficial effects of the II genotype under hypoxic 
conditions may indeed be masked. However, in order to strongly suggest this 
hypothesis, those summiteers who have ascended Mount Everest without the use of 
supplementary oxygen must be tested for ACE genotype identification in a future 
study, in hope to show the advantages of the II genotype, if indeed any exist at all.
In conclusion, a self-selective advantage of the II genotype in climbers successfully 
ascending Mount Everest was not obseiwed, but instead, an equal allele frequency was 
found; all summited however, using supplementary oxygen.
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CHAPTER 6
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This thesis explored physiology and genetic predisposition of humans during 
performance in mountainous environments. Firstly, the physiological responses 
(objective and subjective) of individuals exposed in a laboratory simulated 
mountainous environment were investigated in order to assess a particular mountain 
rescue equipment. Secondly, the physiological responses during rapid and slow 
ascents of mountaineers to altitude were examined. Finally, the possibility that a 
genetic variance may influence performance at altitude was investigated.
The focus of the first study was on the means by which, after an accident occurs, the 
rescue party can prevent hypothermia in a casualty. Mountain rescue teams can 
achieve this thiough the use of the casualty rescue bag, by placing the casualty inside 
the casualty bag (CB). Previous work by Grant et al, (2002) assessed casualty rescue 
bags cuiTently used across Scotland by rescue teams, for effectiveness in protecting a 
victim from already established or a potential hypothermic state. The objective was to 
assess a rescue equipment in the form of a casualty rescue bag, but entirely composed 
of a 1 layer bubble-wrap (BW) and used amongst the Norwegian mountain rescue 
teams. The CB that performed best in the Grant et al, (2002) study was compared 
against this mountain rescue innovation. 12 volunteer subjects were exposed in an 
environmental chamber, under cold (-10°C) and windy (wind speed 2.7 m-sec'^) 
conditions. During equal timed intervals, subjects had their V0 2 , Tgkin, Tcore, and HR 
measurements recorded, as well as an assessment of their subjective responses to 
shivering and cold perception. The results showed that under the tested experimental 
conditions the BW bag did not protect the subjects as efficiently as the CB. Though 
there were no differences in Tcore drop, Tgkin was lower in the BW, and moreover, the 
subjects felt colder and shivered more in the BW. It is not unusual to encounter the 
environmental conditions imposed during this study in the Scottish Highlands or a 
number of mountain ranges worldwide (Alps or Himalayas). However, the specific 
environmental conditions, ‘cold’ and ‘windy’, aie not generally representative of 
many mountain conditions, as ‘wetness’ is present in places such as Scotland and 
Norway. Testing in a wet enviromnent would be rather difficult to standardise, as it 
would be difficult to maintain the same amount of wetness at the same sites in all of 
the subjects. Nonetheless, it was demonstrated that the CB offers higher protection in
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comparison to the already used BW protective equipment. A future study on BW 
efficiency could include 2, or even 3 layers of BW. This would still have a lower 
weight and bulk than a standard CB.
Then a field study was undertaken in the French Alps. The research took place in a 
refuge hut at an altitude of 3817m. 285 volunteer climbers who aspired to ascend 
Western Europe’s highest mountain, Mont Blanc, 4807m, were investigated during a 
rapid ascent profile (2-3 days) starting from the Chamonix valley (1100m). The aim 
was to determine the factors affecting a climber’s ability to ascend Mont Blanc, and to 
investigate what influence genetics would have in their performance. The volunteers 
had their physiological responses of SaOi, ETCO2 , HR, and RR measured, while they 
subjectively assessed, through the use of a questionnaire, how they felt in order to 
determine whether they had established AMS. Their climbing history and other 
demographic variables were also documented. The data was recorded before and after 
their attempted ascent to the summit, and their performance on the mountain (success 
or failure to reach the summit) was documented. Furthermore, considering it may 
have an influence on performance, a genetic sample was obtained to identify their 
angiotensin converting enzyme (ACE) genotype. It was shown that climbing profile 
over the past 14 days prior to an attempted ascent significantly affected ascent 
outcome and time to the summit. Those with recent exposure to >4000 meters had an 
advantage in attempting this peak, while their AMS incidence was lower and Sa02 
levels higher. Older climbers (>57 years) and females had slower ascent times than 
those of younger males. Reports from some subjects indicated that their companions 
did not want to be tested, as they felt unwell. Thus, the small number of subjects who 
failed to reach the summit may be unrepresentative and consequently the results 
regarding the failure rate may be misleading. In an attempt to recruit a less biased 
sample, a future study could include testing climbers in a staged and progressive 
manner. In order to recruit a more representative sample, testing would start at low 
altitudes as it is presumed that all climbers would be well at low altitudes. Then, it 
would be important to follow up on all climbers at all testing altitudes.
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On the genetics front, the first prospective reports were provided in assessing ACE 
genotype and its influence on AMS status after arrival to altitude, and return from a 
subsequent attempt to attain a higher altitude, in this case the Mont Blanc summit. No 
homozygote genotype advantages were observed on AMS onset or severity on either 
Day 1 or 2. However, it was shown that the I-allele of the ACE gene was associated 
with greater success at high altitude. I-allele frequency in those successfully reaching 
the summit was more than twice higher compared to the one for those who failed. Of 
those climbers who failed to make the summit, none were of the II genotype. As with 
any such study, replication and extension are to be recommended. A limitation was 
the low follow-up, almost 25% of individuals never reported back on Day 2 and were 
unavailable for reassessment. Nevertheless, it is thought that this was not a source of 
bias for the genetics analysis; genotype distribution amongst this group was no 
different from those who used the same route of descent as ascent.
Research was continued at similar altitudes, however, this time during a slow and 
staged ascent; a trek from Tumlingtar (330m) to Chamlang Base Camp (5000m) in 
the Hungu valley of the Nepalese Himalayas over 19-21 days. 55 volunteers had their 
physiological responses (SaOz, and HR) and AMS status recorded, daily. The 
variables were subsequently correlated to their ACE genotype, while assessment of 
their hypoxic ventilatory response (HVR) was used in an attempt to predict their daily 
physiological responses as altitude changed over time. As this was a particularly slow 
ascent profile, no major physiological differences between genotypes were 
anticipated. It was foimd that the lEs had lower daily SaOb values than the DD’s and 
ID’s. Day-to-day analysis however, showed that the overall lower significance in 
Sa02 in the IPs might may not be physiologically meaningful after-all, while the low 
number of IPs in the group is speculated to have negatively affected the results. 
Daily HR and AMS did not differ between genotypes either. A predicative ability for 
daily AMS, HR and Sa02, via the use of the HVR measurement was not observed. It 
is recommended that future studies of this kind have genotype groups as similar as 
possible, while investigation of the effects of HVR on daily measurements during a 
fast ascent profile to similar altitudes would be of valuable information.
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Finally, this thesis ended with an investigation on human performance and genetic 
predisposition in climbers attempting to summit Mount Everest. While Everest stands 
at 8850m, its summit is the highest and most hypoxic point man can encounter on the 
surface of this earth. The ACE genotype of 64 climbers was assessed in order to 
determine any relationships between summit success and genotype. It was found that 
there were no genotype differences in those who successfully reached the summit. 
Instead, an equal allele frequency was observed. It is believed that the beneficial 
effects of ACE activity may be limited to acute hypoxic exposure, and thus the most 
probable reason why no genotype self-selection was observed. Furthermore, the use 
of supplementary oxygen at extreme altitudes, is likely to have further masked the 
probable I-allele and 11 genotype advantage.
During all field studies, such as the ones described in this thesis, there are many 
unpredictable factors. It is not easy to eontrol for the ‘willingness’ of the participating 
subjects to perfoiTn all suggested and planned testing. In particular it was noted that 
as subjects became unwell they were reluctant to continue with the testing, or even be 
tested in the first place. This was unfortunate as those subjects would have been of 
distinct interest in the studies. In future studies, data colleetion from sueh subjects 
would be recommended in order to gain a better physiological insight in those not 
able to perform optimally at altitude, although, and as observed in this thesis, such 
attempts may not always prove fruitful.
In closing, one should consider if the incentives in undertaking this kind of genetic 
research, hoping to identify the polymorphic loci implicated in the inter-individual 
variations in performance, are worth the time, money, and effort invested. In this 
thesis the ACE gene was presented as an example of many genes whose one or more 
multi-functioning polymorphisms could only contribute to altering perfoimance 
ability, which could also account for the observed inter-individual perfoimance 
variation. As Payne and Montgomery (2004) explain, such research would identify 
the root of these variations in performance ability, the genes responsible can be 
known, the mechanisms that highlight the observed phenotypes will be uncovered, 
and finally information from all these physiological processes can be applicable to
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human pathological states. A common question arising from the exercise and 
spoiling community is whether or not selection of ultimate performers could be based 
on genetic testing alone. The conservative answer is probably ‘no’, although, it is 
possible that individuals possessing the most complimentary combinations of gene 
variants could be identified in the future. However, identification of the genes 
regulating physical performance is still in the early stages of research. A ‘single gene 
for performance’ is unlikely to be identified, as elite performance depends on a 
number of variations in a number of genes, and finally being influenced by a number 
of enviromnental factors (Payne and Montgomery, 2004). Therefore, in the future, 
one would have to be genotyped for numerous polymorphisms, provided all involved 
in physical performance have been identified; in the meanwhile, a much 
straightforward way is to simply observe one’s performance under the discipline of 
interest. Finally, it should be emphasized that ‘optimal’ genetics alone cannot 
guarantee success. The psychological factors involved are also decisive for success 
during performance, as is keeping focused during competition or under a stressful 
situation, such as in extreme hypoxia, whilst, in the ‘death zone’.
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Figure 6.1
On the summ it o f  Mount Everest. Photo taken by author on May 1S'** 2004, the first Greek climber to ascend from the 
‘classic’ North Side route attempted by Mallory and Irvine in the 1920’s, successfully ascended first by the Chinese in I960, 
and last, but not least, the first solo ascent w ithout the use o f  supplementary oxygen by Reinhold M essner in August o f 1980. 
To this day, author still chooses not to be tested for ACE genotype identification.
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Appendix A
Lake Louise Acute Mountain Sickness Scoring Scale 
(Roach et al, 1993)
Self-Assessment Section
HEADACHE
0 none at all
1 mild headache
2 moderate headache
3 severe/incapacitating headache
GASTROINTESTINAL SYMPRQMS
0 good appetite
1 poor appetite
2 moderate nausea or vomiting
3 severe/incapacitating nausea and vomiting
FATIGUE AND/OR WEAKNESS
0 not tired or weak
1 mild fatigue/weakness
2 moderate fatigue/weakness
3 severe fatigue/weakness
DIZZINESS/LIGHTHEADEDNESS
0 none
1 mild
2 moderate
3 sever s/incapacitating
DIFFICUTLY SLEEPING East nightl
0 slept as well as usual
1 did not sleep as well as usual
2 woke many times, poor night’s sleep
3 could not sleep at all
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Appendix B
Studies 3A and 3B, Subject Questionnaire
BEFORE Ascent to Mont Blanc
Name (Print)..................................................... Male/Female Age.
e-mail address:................................................................................................ Country.
Time....................
1. Are you taking medication to prevent altitude problems? YES NO
if YES please state?...................................................
for how long?................................................
2. Have you had altitude sickness in the past? YES NO
3. At what altitude do you normally reside?................................
4. At which altitudes have you been over the past 14days (residing and elimbing)?
5. What was your route to the Gouter Hut, and how long did it take you to get here?
6. Have you climbed Mont Blanc before? YES NO
7. What is the highest altitude you have ever achieved?
Date.
FOR RESEARCHER
USE ONLY
EtC 02 upper ..........
lower..........
Sa02 upper ..........
lower..........
H .R . upper ..........
lower..........
R.R. upper ..........
lower..........
A.M.S............................
Gene sample
YES/NO
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AFTER Descent
Name (Print). 
Date................. Time....................  Time o f return to hut.
1. Did you make the summit? YES NO
if YES how long did it take to go up from the Gouter Hut? Hrs M ins......
how long did it take to come down from the summit to the Gouter Hut? Hrs Mins.
if NO where did you turn back?
what was the reason? (please circle) 
fatigue
breathlessness 
headache 
bad weather 
you injured yourself
another member o f  the group was injured or could not continue
2. How many climbers were there in your climbing group?....
3. Did you have a professional guide with you? YES NO
FOR RESEARCHER 
USE ONLY
EtC0 2  upper .......
lower.........
Sa02 upper .......
lower.........
H .R . upper........
lower.........
R.R. upper........
lower.........
A.M.S............................
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Ethnicity: Please circle what is most appropriate
1. White
Country
3. Asian
H Indian 
J Pakistani 
K Bangladeshi
L Any other Asian background
5. Other Ethnic Groups
R Chinese 
S Hispanic
T Any other ethnic group
2. Mixed
D White and Black Caribbean 
E White and Black African 
F White and Asian 
G Any other mixed background
4. Black
M Caribbean 
N African
P Any other Black background
6 . Not Stated 
Z Not stated
Are you a smoker? Yes / No
if  YES, how many cigarettes/how much pipe tobacco per day?
I  U N i V E H s r r /  !
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